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CHAPTER I 
 
BACKGROUND AND SIGNIFICANCE 
 
1.1 Angiogenesis 
 
Angiogenesis is the formation of new capillaries from the existing 
vasculature. Angiogenesis is an essential part of female reproductive functions, 
embryonic growth and development, and tissue repair and regeneration. 
However, even in these circumstances, angiogenesis is strictly regulated and 
briefly activated (1). Many pathological processes, such as arthritis and 
tumorigenesis, are characterized by persistent, abnormal angiogenesis. 
The microvasculature consists of endothelial cells and their basement 
membranes, and pericytes. The vascular endothelium is relatively quiescent, with 
one of the most infrequent rates of mitotic division in the body, dividing 
approximately once every three years (2). Certain pathological conditions, 
however, change the resting phenotype to an angiogenic phenotype, resulting in 
the establishment of a new capillary network. Studies have shown that 
angiogenesis is a well-defined process that occurs in the following stages (3-8):  
 Angiogenic growth factors are released in response to tissue injury    
           and hypoxia.  
 Endothelial cells produce proteinases that degrade the 
microvascular basement membrane and the extracellular matrix. 
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 Endothelial cells migrate through the basement membrane and  
           extracellular matrix.  
 Endothelial cells proliferate, and form tubes and lumena. 
 Nascent endothelial cell tubes anastomose, forming a vascular  
           network. 
 Smooth muscle cells and pericytes are recruited to the vasculature,  
           leading to microvascular stabilization. 
 
1.2 Ocular angiogenesis 
 
Pathological ocular angiogenesis is commonly referred to as ocular 
neovascularization (NV). NV is a central feature of retinopathy of prematurity 
(ROP), proliferative diabetic retinopathy (PDR), and age-related macular 
degeneration (AMD); the leading causes of blindness in infants, working age 
individuals, and the elderly, respectively (9-11). Although NV tends to occur at a 
relatively late stage in the course of many ocular disorders, it is nonetheless a 
highly attractive target for therapeutic intervention, because it represents a final 
common process in diseases that are multi-factorial in etiology, and it is the event 
that leads directly to vision loss. Vision loss is due to the pathologic nature of the 
blood vessels that develop in these disease conditions; they are fragile, non-
patent, and leaky, and fibrovascular proliferation and migration into the vitreous 
ultimately leads to tractional retinal detachment. 
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A recent review article employed multiple epidemiologic studies and U.S. 
census data to estimate the prevalence of ROP, PDR, and AMD (12). Based on 
this work, individuals affected by neovascular forms of ROP, DR, and AMD 
collectively number well into the millions of Americans. Other retinal conditions 
with neovascular sequelae, such as sickle cell retinopathy and vascular occlusive 
disorders, are less prevalent, but remain clinically significant.  
Prior to 2005, laser photocoagulation was the prevailing treatment for 
conditions characterized by ocular NV. Laser photocoagulation involves 
cauterizing blood vessels with the heat of a fine-point laser beam. This ablative 
approach offers short-term benefits to certain subgroups of patients (13-15), but 
is associated with significant adverse effects (16,17). Laser photocoagulation 
burns and destroys part of the retina, and therefore results in some permanent 
vision loss. Laser photocoagulation may cause some loss of central and 
peripheral vision, worsened night vision, and a decreased ability to focus. 
Moreover, because this approach fails to address the underlying stimuli that 
initiate pathologic blood vessel growth, it is associated with high rates of 
persistent and recurrent disease (14,18), accompanied by an increased 
frequency of severe vision loss (19). 
Because of the clear limitations of this treatment for ocular NV, there is a 
compelling need to develop new, rational therapeutic approaches. One attractive 
approach is to target the underlying pro-angiogenic stimuli, so as to achieve a 
sustained therapeutic effect. The development of such treatments depends on a 
clear understanding of the cellular and molecular processes involved in 
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angiogenesis, and of the specific characteristics of these processes within the 
tissues of the eye. 
 
1.3 Molecular mechanisms of ocular angiogenesis 
 
Ischemia-induced hypoxia is a central feature of ROP and PDR, and may 
worsen AMD, and other neovascular disorders of the eye. It has long been 
accepted that hypoxia stimulates retinal angiogenesis (20,21). In 1948, 
Michaelson first proposed that retinal hypoxia stimulates the production of a 
diffusible angiogenic factor. Since that time, various pro-angiogenic growth 
factors have been identified, each mediating a number of diverse angiogenic cell 
behaviors. Of the growth factors involved in retinal angiogenesis, VEGF-A is 
thought to be a principal mediator (22). 
VEGF-A is the prototypical member of the VEGF family of growth factors.  
This family includes placental growth factor (PlGF), VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, and the virus encoded VEGF-E. VEGF-A is hereafter referred to as VEGF.  
VEGF is a 46 kD homodimeric glycoprotein that serves as a cell survival factor, 
vasopermeability factor, and angiogenic growth factor (23). VEGF protein is 
produced via alternative splicing of a single VEGF gene, yielding five distinct 
variants comprised of 121, 145, 165, 189, and 206 amino acids (24). The 121, 145, 
and 165 variants are diffusible, whereas the larger VEGF variants (189 and 206) 
remain bound to the cell surface and the extracellular matrix through their interaction 
with, and binding affinity for, heparin (25). Major splice variants, and the exons that 
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comprise them, are depicted in Figure 1. Exons 1–5 contain the VEGF receptor-
binding domain, while exons 6 and 7 contain heparin-binding domains.  
Hypoxia has been shown to regulate VEGF activity at the level of: gene 
transcription, mRNA stability, translation, and protein secretion (26). Chronic 
tissue hypoxia induces VEGF production through the transcriptional activator 
hypoxia-inducible factor 1 (HIF-1).  HIF-1 accumulates as a result of low oxygen, 
Figure 1. The associations between VEGF family members and the VEGF receptors. Also 
shown are the major VEGF variants formed by alternative splicing of the VEGF gene. The 
splice variants differ in their expression of exons 6 and 7, which mediate heparin binding, and 
therefore, the solubility of the splice variants. 
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binds to hypoxia response elements (HREs) in the promoter regions of various 
genes, and stimulates the expression of hypoxia-inducible genes and angiogenic 
growth factors like VEGF (27-31). In the retina, hypoxia-induced VEGF 
production has been demonstrated most consistently and dramatically in the 
Müller cells, the predominant glial cells within the retina (32-34). 
VEGF production is also regulated by stimuli other than hypoxia. In fact, a 
variety of stimuli, including other growth factors, cytokines, hormones, and 
cellular stressors activate VEGF, particularly at the level of transcription. These 
stimuli ultimately activate various transcription regulatory factors, which bind to 
promoter regions on the VEGF gene. Some of the transcription factors that bind 
to VEGF promoter regions and activate VEGF transcription are: AP-1, AP-2, 
CREB, Egr-1, HIF, Sp1, Sp3, and STAT3 (for a comprehensive review, see 35). 
After VEGF is produced and secreted by Müller cells, and to a lesser 
extent other cell types, it binds with high affinity to its cognate tyrosine kinase 
receptors expressed on the surface of endothelial cells, VEGFR-1 (Flt-1) and 
VEGFR-2 (KDR or Flk-1) (23). VEGF-VEGFR signaling plays a critical role in the 
physiological angiogenesis that takes place as a normal part of embryonic growth 
and development. Inactivation of even a single allele of the VEGF gene results in 
embryonic lethality (36). Formation of blood vessels is severely impaired in mice 
lacking a single allele of the VEGF gene. VEGF knockout embryos also 
demonstrate defective vasculogenesis, large vessel formation, capillary 
sprouting, and remodeling of the yolk sac vasculature. Furthermore, inactivation 
of either Flt-1 or Flk-1 results in embryonic lethality (37,38). Flt-1 null mice exhibit 
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vascular disorganization. Flk-1 null mice exhibit severely disrupted 
hematopoiesis, vasculogenesis, and endothelial cell differentiation. These 
findings point to the importance of VEGF and its receptors in physiological, 
developmental angiogenesis. By extension, retinal vascular development is 
dependent upon VEGF signaling. 
Findings from several studies demonstrate the importance of, and 
interaction between, VEGF and the VEGFRs, to the development of the retinal 
vasculature (39-45). In both humans and animals, VEGF expression is first seen 
in astrocytes, which are located adjacent to the inner limiting membrane of the 
retina. The astrocytes, and VEGF expression, advance from the optic nerve-head 
towards the retinal periphery. This wave of VEGF expression precedes the 
development of the retina’s superficial vascular net (40,42,46,47). Once the 
vessels reach the peripheral extent of the retina, VEGF expression disappears 
from the superficial vascular net, and is instead expressed by Müller cells in the 
inner nuclear layer of the retina (40). This second wave of VEGF expression is 
responsible for driving the development of the retina’s deep vascular net.  In 
total, these studies demonstrate that VEGF expression in the retina is both 
temporally and spatially related to the development of the retinal vasculature.  
 Mice expressing only VEGF-164 demonstrate normal retinal vascular 
development. Alternatively, mice expressing only VEGF-120 demonstrate 
retarded venous and arterial development; and mice expressing only VEGF-188 
demonstrated normal venous development, but little retinal arterial growth (48).  
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While both VEGFR-1 and VEGFR-2 play critical regulatory roles in 
developmental angiogenesis, the neovascular effects of VEGF are primarily 
mediated through VEGFR-2 signaling (49). Upon VEGF binding, VEGFR-2 
dimerization and tyrosine autophosphorylation initiate complex signal transduction 
cascades that result in diverse endothelial cell behaviors. These VEGF-induced 
behaviors include survival, proliferation, migration, and nitric oxide production 
leading to increased vascular permeability (23,50-54). Thus, VEGF signaling through 
Figure 2. VEGFR-2 signaling pathways leading to angiogenic endothelial cell activities. 
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VEGFR-2 activates the angiogenic phenotype in endothelial cells, and these 
behaviors result in retinal NV (Figure 2). 
Inhibition of VEGF using anti-sense oligonucleotides, chimeric proteins, 
monoclonal antibodies, and VEGF peptides has been shown to inhibit oxygen-
induced retinal angiogenesis in animals and humans (55-58). Inhibition of KDR, 
and the use of soluble Flt-1 have both been proven efficacious at reducing the 
severity of retinal NV in animal models of ocular angiogenesis (59, 60). The 
results obtained lend support to the strategy of targeting VEGF induction and/or 
activity as an appropriate ocular therapeutic modality. 
 
1.4 Current treatments 
 
VEGF is widely regarded as a principle growth factor mediating the 
development of ocular NV (22). This belief has led to the development of a class 
of therapeutics for the treatment of neovascular AMD based on VEGF 
antagonism (61,62). These treatments are the only FDA-approved alternatives to 
ablative laser photocoagulation, previously discussed. VEGF antagonists 
currently employed in clinical practice include: pegaptanib (Macugen®, Pfizer), 
an RNA-like aptamer that binds and inhibits VEGF-165, the predominant 
pathologic splice variant of VEGF; bevacizumab (Avastin®, Genentech), a 
humanized mouse monoclonal antibody to human VEGF that was approved for 
systemic administration in the treatment of cancer, but is used off-label in the 
treatment of AMD; and ranibizumab (Lucentis®, Genentech), the F(ab) fragment 
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of an anti-VEGF similar to Avastin®, which is approved for use in AMD. The 
therapeutic efficacy of these VEGF antagonists has been remarkable, although 
there are important limitations that stem, in part, from the requirement to 
administer the antagonists by frequently repeated intravitreal injections. In 
addition to the discomfort and costs associated with the procedures, this 
approach leads to high peaks levels and prolonged trough levels of antagonist, 
during which time it is sub-therapeutic. This unfavorable pharmacokinetic profile 
may contribute to reduced efficacy, as exemplified by the incomplete arrest of 
disease progression observed in many patients, and the frank resistance to 
therapy that characterizes others. Periods of very high levels of the antagonist 
may contribute to both local and systemic toxicity. Morbidity related to the 
intravitreal injections is another important limitation of the current treatment 
regimen (63). The most frequent and problematic injection-related toxicity is the 
development of endophthalmitis, a potentially blinding condition (64), observed at 
a rate as high as 1.3% per patient per year in clinical studies. This toxicity is 
expected to rise as the treatment becomes part of standard practice and is 
performed outside of the rigorous settings of clinical trials in academic centers.  
Finally, it remains unclear if chronic administration of anti-VEGF drugs will exert a 
negative influence on the retinal neurons that are known to express VEGF 
receptors or on the sensitivity and responsivity of the retinal or choroidal 
vasculature to VEGF stimulation. In fact, it is likely that chronic inhibition of VEGF 
may lead to increased VEGF receptor expression (our unpublished findings), 
which may worsen the angiogenic response if the therapy is not maintained.  
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Thus, although VEGF-centric therapies clearly reduce NV, they do not 
completely eliminate it. Combination therapies, or therapies that simultaneously 
target more than one point along the angiogenic cascade (e.g. up- and down-
stream of VEGF receptor activation), are an unmet need in ophthalmology. 
Therapeutics designed to target the angiogenic cascade at more than one point 
have the potential to provide a more powerful and effective therapeutic target for 
angiogenic diseases of the eye. In order to design such therapeutics, a solid 
understanding of the molecules with more than one role in the process is 
necessary. 
 
1.5 COX-2 
 
The cyclooxygenase (COX) enzymes are responsible for catalyzing the 
production of prostaglandin H2 (PGH2) from membrane-derived arachidonic acid. 
PGH2 is an unstable intermediate that is rapidly converted, by tissue- and cell-
specific synthases, to biologically active prostaglandins (PGD2, PGE2, PGF2, 
PGI2) and thromboxanes (TXA2) (Figure 3). There exist at least two isozymes of 
COX, COX-1 and COX-2, the products of two different genes located on two 
different chromosomes. The two enzymes catalyze identical reactions and retain 
60% amino acid sequence identity. COX-1, however, is typically regarded as a 
housekeeping enzyme whose constitutive expression and prostanoid 
[prostaglandin (PG) and thromboxane] products are responsible for maintenance 
of the gastric mucosa, platelet aggregation, and regulation of the renal 
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vasculature (65). COX-2, on the other hand, is the product of an immediate early 
gene, and it can be induced by mitogens, cytokines, and tumor promoters (66).  
Once the COX enzymes catalyze their production, prostanoids bind to 
their cognate G-protein-coupled receptors (GPCRs) on the surface of target cells. 
The receptors determine the extent and biological activity of the prostanoids. 
PGF2, PGI2, and TXA2 signal through the FP, IP, and TP receptors, respectively. 
PGD2 signals through the DP and CRTH2 receptors. PGE2 signals through the 
EP1, EP2, EP3, and EP4 receptors. Signaling through DP, IP, EP2, and EP4 
Figure 3. The cyclooxygenase cascade. In response to some stimulus, cPLA2 liberates 
arachidonic acid from membrane phospholipids. The COX and prostanoid synthase enzymes 
then convert arachidonic acid to the five biologically active prostanoids. 
  13 
stimulates the activation of adenylyl cyclase (AC), resulting in increased cyclic 
AMP (cAMP) production. Signaling through EP3 and CRTH2 results in reduced 
cAMP production. Signaling through FP, TP, and EP1 results in calcium 
mobilization (67). The precise tissue-specific and cell-specific signaling pathways 
and the biological roles mediated by each of the prostanoid receptors have yet to 
be determined. 
COX-2 is elevated in various cancers, including colorectal cancer. Patients  
who regularly take non-steroidal anti-inflammatory drugs (NSAIDs) for the 
treatment of chronic pain and heart disease demonstrate a 40-50% reduction in 
the incidence and severity of colorectal cancer (68). NSAIDs are compounds that 
inhibit the activity of the COX enzymes. These findings led to the suggestion that 
COX-2 and the prostanoids may act as tumor promoters (69,70).  At least one 
tumor-promoting function of the prostanoids is the stimulation of angiogenesis 
(71-73). 
The prostanoids exhibit angiogenic effects both up- and downstream of 
growth factor production. Upstream, the prostanoids have been shown to 
mediate the expression of pro-angiogenic molecules. They have been shown to 
induce VEGF and bFGF in various cell types (70,74-76). Researchers studying 
angiogenesis related to various cancers and other neovascularizing conditions 
have demonstrated, using pharmacological and genetic manipulation of COX-2, 
that COX-2 inhibition resulted in reduced VEGF production, in vitro and in vivo 
(77-80). Downstream, pro-angiogenic factors such as hypoxia, VEGF, bFGF, 
TNF-α, and IL-1 have been shown to induce endothelial cell expression of COX-2 
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(81-84), and COX-2-derived prostanoids stimulated proliferation, migration, and 
tube formation in human umbilical vein endothelial cells (HUVEC) (85). COX-2-
selective inhibitors have been shown to block the proliferation and migration of 
vascular endothelial cells (86-89). Several prostanoids have been shown to 
induce angiogenesis in various angiogenesis assays and cancer models 
(72,73,90-92). Furthermore, specific inhibition of COX-2 has been shown to 
inhibit angiogenesis in the cornea or within experimental tumors (93-96), and this 
anti-angiogenic effect can be reversed by prostaglandin treatment (81,91). 
 
1.6 COX-2 and the eye 
 
COX-2 has been localized to various ocular tissues, and its expression 
has been found, or can be induced, in the following structures: cornea, iris, 
cilliary body, various cell types within the neuroretina, and the retinal pigment 
epithelium (RPE) (95,97-100). The expression of the COX-2 enzyme in these 
ocular tissues suggests a functional role for its prostanoid products. Indeed, 
ocular prostanoids have been shown to mediate the cornea’s inflammatory 
response (101,102), intraocular pressure (103,104), retinal blood flow (105), and 
maintenance of the blood-retinal-barrier (106). Additionally, inhibition of COX has 
been effective at reducing the production of VEGF and corneal, retinal, and 
choroidal NV in relevant models of ocular disease. 
In experimental models of corneal angiogenesis, various groups have 
demonstrated that the non-selective NSAIDs indomethacin and ketoprofen, as 
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well as the COX-2-selective agent NS-398 significantly reduced the severity of 
NV (95,107,108). In experimental models of retinal angiogenesis, investigators 
have demonstrated that inhibiting various points along the COX cascade reduced 
pathological NV. Cytosolic phospholipase A2 (cPLA2) is the enzyme responsible 
for liberating arachidonic acid, the substrate for the COX enzymes, from 
membrane phospholipids. Rodents treated with a cPLA2 inhibitor demonstrated 
reduced oxygen-induced retinal NV (109). Non-specific inhibitors of COX such as 
nepafenac, as well as COX-2-selective inhibitors such as APHS, etodolac, and 
rofecoxib, have all been shown to have a similar anti-angiogenic effect 
(77,110,111). In models of laser-induced choroidal NV (LCNV), nepafenac, 
etodolac, and lumiracoxib (another COX-2-selective agent), all effectively 
inhibited the development of CNV (77,112,113). These data suggest that COX-2 
mediates various aspects of corneal, retinal, and choroidal NV.  
In summary, although various groups have demonstrated the efficacy of 
COX inhibition at reducing ocular NV, little work has been done to determine 
which of the COX-2 derived prostanoid(s) is (are) involved in mediating VEGF 
production, downstream angiogenic endothelial cell behaviors, and ocular 
angiogenesis. Because of this gap in ocular angiogenesis research, we 
examined the specific involvement of COX-2 and COX-2-derived prostanoids in 
ocular angiogenesis. Figure 4 very generally depicts our working model of the 
role of COX-2 in angiogenic cell behaviors, with implications for conditions 
characterized by retinal NV. The goal of our research was two-fold. We wanted to 
1) better understand the role of COX-2-derived prostanoids in ocular angiogenic 
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disease, and 2) use the knowledge gained through our research to identify more 
specific therapeutic targets. 
 
Figure 4. Schematic distillation of retinal angiogenesis. We typically distill retinal angiogenesis 
into its two most basic components, growth factor production and growth factor consumption. In 
these studies, we examined the role of COX-2, COX-2-derived prostanoids, and the prostanoid 
receptors on hypoxia-induced VEGF production by Müller cells and VEGF-induced angiogenic 
cell behaviors by endothelial cells. 
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2.1 Abstract 
 
Nepafenac is a potent NSAID that rapidly penetrates the eye following 
topical ocular administration. In the eye, nepafenac is converted to amfenac, 
which has unique time-dependent inhibitory properties for COX-1 and COX-2. 
The purpose of the present study was to investigate the capacity of amfenac to 
inhibit discrete aspects of the angiogenic cascade in vitro, and to test the efficacy 
of amfenac and nepafenac in vivo, using the rat OIR model.  
Müller cells were treated with amfenac, celecoxib (COX-2), or SC-560 
(COX-1), and hypoxia-induced VEGF and PGE2 were assessed. Endothelial cells 
were treated with amfenac, celecoxib, or SC-560, and VEGF-induced 
proliferation and tube formation were assessed. Rat pups were subjected to OIR, 
received intravitreal injections of amfenac, celecoxib, or SC-560, and 
neovascularization (NV), prostanoid production, and VEGF were assessed. 
Other OIR-exposed pups were treated with topical nepafenac, ketorolac, or 
diclofenac, and inhibition of NV was assessed. 
Amfenac treatment failed to inhibit hypoxia-induced VEGF production. 
Amfenac treatment significantly inhibited VEGF-induced tube formation and 
proliferation by endothelial cells. Amfenac treatment significantly reduced retinal 
prostanoid production and NV in OIR. Nepafenac treatment significantly reduced 
retinal NV in OIR; ketorolac and diclofenac had no effect. 
Nepafenac and amfenac inhibit OIR more effectively than the 
commercially available topical and injectable NSAIDs used in this study. Our data 
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suggests that there are COX-dependent and COX-independent mechanisms by 
which amfenac inhibits OIR. Because it is bioavailable to the posterior segment 
following topical delivery, nepafenac appears to be a promising advancement in 
the development of therapies for neovascular eye diseases. 
 
2.2 Introduction 
 
Pathological ocular angiogenesis, or ocular neovascularization (NV), is a 
pivotal pathologic feature of several prevalent, sight-threatening eye diseases. In 
developed countries, retinopathy of prematurity (ROP), proliferative diabetic 
retinopathy (PDR), and age-related macular degeneration (AMD) are the leading 
causes of irreversible blindness in infants, working-age adults, and the elderly, 
respectively (9,10,12). Clinical and experimental evidence suggests that 
ischemia-induced hypoxia is a central etiological factor in retinal NV (114,115). 
For example, several retinal cell types respond to hypoxia by up-regulating 
production of vascular endothelial growth factor (VEGF), the principal growth 
factor promoting retinal NV (32,33,116). Among these retinal cells, Müller cells 
exhibit the most consistent and dramatic increase in VEGF synthesis and 
secretion when subjected to experimental hypoxia (32-34). VEGF binds with high 
affinity to VEGF receptors (VEGFR-1 and VEGFR-2) expressed on the surface of 
endothelial cells, initiating signal transduction cascades that lead to angiogenic 
endothelial cell behaviors (51-53,55). 
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Cyclooxygenase (COX) enzymes are responsible for the biosynthesis of 
prostanoids [prostaglandins (PG) and thromboxanes] from arachidonic acid. 
Studies suggest that COX-1, the constitutively active isoform of COX, plays a 
role in angiogenic cell behaviors and carcinogenesis (117-122). Additionally, 
evidence suggests that the inducible isoform of COX, COX-2, plays a key role in 
regulating angiogenesis through the induction of prostanoid synthesis. 
Prostanoids subsequently induce the expression of pro-angiogenic factors such 
as VEGF and bFGF in many cell types (75,76), and several prostanoids have 
been shown to induce angiogenesis in in vitro and in vivo assays of human 
angiogenesis and cancer (72,73,90-92). A subset of prostanoids, under some 
conditions, have been shown to be deleterious to the retinal vasculature in ways 
other than promoting growth factor production. Prostanoid levels are higher in the 
retinas of infants than in the retinas of adults (123,124). Prostanoids are involved 
in maintaining retinal and choroidal blood flow (125,126). Specifically, the infant’s 
retinal prostanoid complement, coupled with their age-dependent responses to 
the prostanoids, leads to increased retinal vascular relaxation and dilation 
(124,127,128). This effect is particularly harmful to premature infants on oxygen 
therapy who do not yet have the ability to auto-regulate retinal and choroidal 
blood flow; prostanoids serve to enhance oxygen delivery to already-saturated 
retinal tissue, which is known to worsen the pathology of ROP (125,129). COX-2-
dependent production of TXA2 can lead to endothelial cell cytotoxicity, worsening 
the retinal microvascular degeneration in ischemic retinopathies (130,131). 
Prostanoid signaling through the EP3, EP4, DP, TP, and IP receptor have all been 
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implicated in mediating discrete cell behaviors that are invovled in the 
development or pathology of ischemic retinopathies (110,132-135). Selective 
inhibition of COX-2 also prevents pathological angiogenesis in the cornea, retina, 
and experimentally-induced tumors (93-96,111). Therefore, non-steroidal anti-
inflammatory drugs (NSAIDs) that inhibit the activity of the COX enzymes may be 
viable pharmacologic agents for the treatment of retinal neovascularization (NV).  
In 2005, the U.S. Food and Drug Administration (FDA) approved the 
topical NSAID, NEVANAC (nepafenac; 0.1% ophthalmic suspension) for the 
treatment of pain and inflammation associated with cataract surgery (136-139). 
The active ingredient in NEVANAC is nepafenac, a potent, reversible COX-1 
and COX-2 inhibitor (Kulmacz RJ, et al. 2007: EVER E-Abstract e473). 
Nepafenac is a pro-drug with superior penetration of cornea and scleral tissues 
(140). It is quickly metabolized in vivo by amidases in the iris/cilliary body and 
retina/choroid to form amfenac (136). Amfenac is an NSAID with antipyretic and 
analgesic properties, and it inhibits both COX-1 and COX-2 activity (137). 
Amfenac, like nepafenac, is a reversible inhibitor of both COX-1 and COX-2, but 
unlike nepafenac, amfenac has unique time-dependent inhibitory properties for 
both COX-1 and COX-2, implying that with time, amfenac irreversibly binds the 
enzymes, accounting for amfenac’s prolonged activity (Kulmacz RJ, et al. 2007: 
EVER E-Abstract e473).  
Topical ocular administration of nepafenac inhibits posterior segment NV 
in mouse models of oxygen-induced retinopathy (OIR) and laser-induced 
choroidal NV (LCNV), and it inhibits the functional abnormalities and retinal 
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vasculopathy observed in rats with streptozotocin-induced diabetes (77,141). 
Topical ocular administration of nepafenac reduced retinal VEGF expression in 
the mouse model of OIR (77). This observation is similar to the reported findings 
demonstrating the anti-VEGF effects of COX-2 inhibitors in tumor angiogenesis 
models (142). 
In order to better understand its bioactivity, we used in vitro assays of 
angiogenic cell behaviors to determine the capacity of amfenac to inhibit discrete 
aspects of the angiogenic cascade in the retina. We evaluated the effect of 
amfenac on hypoxia-induced VEGF production by Müller cells. Then, we looked 
at the effect of amfenac on VEGF-induced angiogenic cell behaviors in retinal 
endothelial cells. To further investigate the therapeutic potential of nepafenac for 
human use, we tested the efficacy of amfenac and nepafenac in vivo, using the 
rat model of OIR developed in our laboratory. This model produces a pattern of 
pathological pre-retinal NV mimicking that of premature infants with ROP (143). 
The results of these studies more fully define the mechanism(s) by which 
nepafenac mediates its anti-angiogenic effect, as well as demonstrate where 
COX enzymes appear to exert their influence during pathologic retinal 
angiogenesis. 
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2.3 Materials and methods 
 
Materials 
Nepafenac (NEVANAC, 0.1% ophthalmic solution), amfenac, and 
vehicle were synthesized and provided by Alcon Laboratories, Inc. Ketorolac 
tromethamine (Acular, 0.5% ophthalmic solution; Allergan, Inc.), diclofenac 
sodium (Voltaren, 0.1% ophthalmic solution; Novartis), and celecoxib 
(Celebrex; Pfizer) were obtained from commercial sources. SC-560 was 
purchased from Cayman Chemical (Ann Arbor, MI). 
 
Isolation and culture of primary rat retinal Müller cells 
Primary rat retinal Müller cell cultures were established from postnatal day 
(P)7 Long Evans rat pups according to well-established methods (144). Briefly, 
enucleated eyes were placed in soaking medium, Dulbecco’s Modified Eagle 
Medium Low Glucose (DMEM; HyClone; Logan, UT) supplemented with 1X 
Antibiotic/Antimycotic Solution (Sigma; St. Louis, MO), overnight. The following 
day, eyes were incubated in digestion buffer, comprised of the soaking medium 
plus 0.1% trypsin and 70 U/ml collagenase, for 60 minutes at 37ºC. Retinas were 
then dissected, triturated, plated, and grown in DMEM supplemented with 10% 
fetal bovine serum and 1X Antibiotic/Antimycotic Solution. Cultures were 
maintained at 37ºC in a 5% CO2/95% air (20.9% oxygen) atmosphere (normoxia) 
in a humidified incubator (NuAire; Plymouth, MN). Müller cells were identified by 
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immunocytochemical staining for cellular retinaldehyde binding protein (CRALBP; 
Abcam; Cambridge, MA). Passages three to six were used for experiments. For 
treatment of Müller cells with hypoxia, a CO2-enriched environment was 
generated with a BBLTM GasPak Pouch system (Becton-Dickinson; Sparks, MD). 
 
Quantitative real time RT-PCR of VEGF in rat Müller cells 
Primary rat Müller cells were seeded in 10-cm Petri dishes at equal 
density and maintained in normoxia. At 80% confluency, the cells were treated 
with vehicle (0.1% DMSO) or increasing concentrations of amfenac (0.1 to 10 
µM) and placed in hypoxia for 24 hours. Total RNA was isolated from the cells 
using Trizol reagent (Invitrogen Corporation; Carlsbad, CA). Each RNA sample 
was quality-controlled for DNA and protein contamination. For VEGF 
amplification, cDNAs were reverse transcribed using the High-Capacity cDNA 
Archive Kit (Applied Biosystems; Foster City, CA) according to manufacturer’s 
instructions. Quantitative real-time RT-PCR was performed in duplicate by co-
amplification of rat VEGF vs. β-actin (endogenous normalization control) in 
separate tubes, using gene-specific TaqMan Gene Expression Assays according 
to the manufacturer’s instructions (Applied Biosystems; primer and probe 
sequences used in this assay are proprietary). 
 
Quantification of rat Müller cell-derived VEGF and PGE2 levels 
Primary rat Müller cells were seeded in 12-well plates at equal density and 
maintained in normoxia. At 80% confluency, cells were treated with vehicle (0.1% 
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DMSO) or 10 µM amfenac, celecoxib, or SC-560, and then maintained in 
normoxia or hypoxia for 24 hours. Culture medium from cells was collected and 
assayed for VEGF and PGE2 concentration with colorimetric sandwich ELISA kits 
(R&D Systems; Minneapolis, MN) according to the manufacturer’s instructions. 
Cells were washed with CMF-PBS (Invitrogen), lysed with cold lysis buffer 
(Promega; Madison, WI), and protein concentration was determined with a 
bicinchoninic acid assay (BCA; Pierce; Rockford, IL). The amount of VEGF and 
PGE2 (pg/ml) in the culture medium was normalized to total protein concentration 
(mg/ml) of cell lysates. 
 
Culture of human retinal microvascular endothelial cells (HRMEC)  
Primary human retinal microvascular endothelial cells (HRMEC; Cell 
Systems; Kirkland, WA) were seeded in tissue culture flasks coated with 
attachment factor (Cell Signaling; Danvers, MA) and cultured with endothelial 
basal medium (EBM; Cambrex; East Rutherford, NJ) supplemented with 10% 
FBS and EGM single quots (Cambrex). When experimental conditions required 
serum free (SF) medium, MCDB 131 medium (Sigma) containing 1X 
Antibiotic/Antimycotic Solution was used. Cultures were maintained at 37ºC in a 
5% CO2/95% air (20.9% oxygen) atmosphere (normoxia) in a humidified 
incubator. 
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HRMEC tube formation assay 
In vitro tube formation by HRMEC was carried out in 12-well plates coated 
with growth factor-reduced Matrigel® matrix (Becton-Dickinson). HRMEC were 
seeded at 3×104 cells per Matrigel-coated well in complete culture medium. After 
4.5 hours, the culture medium was removed and the cells were treated with SF 
medium alone or SF medium containing 25 ng/ml VEGF (R&D Systems) in the 
presence or absence of amfenac, celecoxib, or SC-560 (0.01 to 1 µM). Twenty-
four hours later, three images of tubes per well were captured using a DMC 
digitizing camera (Polaroid; Cambridge, MA) mounted on an IMT-2 inverted 
microscope (Olympus; Melville, NY). Capillary-like structures were measured 
using Image J software (NIH; Bethesda, MD), and the mean tube length per area 
of the field was calculated for each well. 
 
HRMEC cell proliferation assay 
VEGF-induced HRMEC proliferation was measured using a modified MTT 
assay. Each well of a 96-well plate was coated with a fibronectin/hyaluronic acid 
(HA) matrix and seeded with 3×104 cells. Complete medium was added and the 
cells were incubated for two days. The medium was then aspirated, and the cells 
were incubated with SF medium overnight. The following day, culture medium 
was removed and the cells were treated with SF medium alone or SF medium 
containing 25 ng/ml VEGF (R&D Systems) in the presence or absence of 
amfenac, celecoxib, or SC-560 (0.01 to 10 µM). Twenty-four hours later, 25 µL of 
a 5 mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
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(MTT; Molecular Probes; Eugene, OR) was added to each well and incubated for 
4 hours under normal growth conditions. One hundred microliters of lysis buffer 
[20% SDS in 50:50 dimethylformamide (DMF) and H2O with 2.0% acetic acid and 
0.05% HCl] was then added to each well, and the plates were incubated 
overnight at 37°C and read (Spectramax 190; Molecular Devices; Sunnyvale, CA) 
at 570 nm. Absorbance values were translated to cell number using standard 
curves consisting of six cell densities assayed in quadruplicate. The data 
obtained from the MTT assay and cell counts using a hemocytometer in the 
presence of trypan blue (Sigma) were found to be highly correlated (r2=0.933, 
data not shown). A standard curve of absorbance at 570 nm vs. HRMEC number 
was then produced. 
 
Oxygen-induced retinopathy (OIR) in the rat 
All animal procedures used in this study were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee and were performed in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. Litters of Sprague-Dawley rat pups and their mothers (Charles 
River Laboratories; Wilmington, MA) were transferred within four hours after birth 
to oxygen exposure chambers where they were subjected to alternating 24 hour 
periods of 50% oxygen and 10% oxygen for 14 days. Control rats were raised 
simultaneously in room air. On postnatal day (P)14, the oxygen-exposed rats 
were returned to room air. 
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Quantification of retinal prostanoids 
On P14, following removal from the oxygen chambers, rats were 
administered amfenac (0.05 µg; 40 µM) or vehicle by single intravitreal injection, 
according to a well-established procedure (145). One day later, on P15, retinas 
were harvested and homogenized. The lipid soluble prostaglandin compounds 
were extracted with a Sep-Pak C18 column (Waters; Milford, MA) and were 
nitrogen-evaporated. O-methoxyamine derivatives were formed by treatment with 
2% methoxyamine-HCl in water at room temperature for 30 minutes. Compounds 
were extracted with ethyl acetate and subsequently converted to 
pentaflurobenzyl esters. The compounds were chromatographed on TLC plates 
with ethyl acetate/methanol. The compounds were then converted to 
trimethylsilyl ether derivatives and analyzed by negative ion chemical ionization 
mass spectrometry coupled with a gas chromatography system (Agilent 
Technologies; Palo Alto, CA). 
 
Quantification of retinal VEGF levels 
On P14, following removal from the oxygen chambers, rats were 
administered amfenac (0.05 µg; 40 µM) or vehicle by a single intravitreal 
injection, according to a well-established procedure (145). Because there is a 
peak in retinal VEGF two days post-oxygen exposure in this model (146), rats 
were sacrificed on P16 and retinas were harvested and subjected to lysis by 
homogenization. The total protein concentration of samples was measured by 
BCA. Retinal VEGF levels were measured with a VEGF colorimetric sandwich 
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ELISA kit (R&D Systems) according to the manufacturer’s instructions. The final 
mass of retinal VEGF was standardized to total retinal protein. 
 
Quantification of retinal neovascularization (NV) 
Using commercially available formulations and drop-tainers, nepafenac 
(0.03%, 0.1%), ketorolac (0.5%), diclofenac (0.1%) or vehicle was dropped 
directly onto the cornea two or four times a day, depending upon experiment. 
Topical dosing was performed between P14 and P19. A separate group of 
oxygen-exposed rat pups received a single intravitreal injection of amfenac (0.05 
µg; 40 µM), celecoxib (0.075 µg; 40 µM), SC-560 (0.07 µg; 40 µM), or vehicle 
(0.1% DMSO) at P14, after return to room air. Our estimations of vitreous volume 
indicate that these concentrations of injected NSAIDs lead to vitreous 
concentrations that fall within the middle range of the concentrations used for in 
vitro assays. Regardless of pharmacologic treatment, all oxygen-exposed rats 
were sacrificed on P20, 6 days following return to room air. The eyes were 
enucleated, and retinas were dissected and placed in 10% neutral buffered 
formalin [CMF-PBS (Invitrogen) with 37% formaldehyde solution (Fisher 
Scientific; Fair Lawn, NJ)] overnight at 4°C. The retinal vasculature was stained 
for adenosine diphosphatase (ADPase) activity, according to well-established 
procedures (147). Images of ADPase-stained retinas were digitized, captured, 
and displayed at 20X magnification. The total retinal area and the retinal area 
containing vasculature were independently measured. For each retinal image, 
pre-retinal vessel tufts were outlined, the pixels within an encircled area were 
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counted, and the total number of pixels from all areas were summed and 
converted to square millimeters.  
 
Statistical analysis 
Data were analyzed with commercial software (JMP; SAS Institute; Cary, 
NC). Analysis of variance (ANOVA) with appropriate post-hoc analyses were 
used to analyze data. 
 
2.4 Results 
 
Intravitreally-injected NSAID efficacy in rat OIR 
The effect of 0.05 µg amfenac on OIR-induced retinal NV was compared 
to two other NSAIDs, 0.075 µg celecoxib (COX-2 inhibitor) and 0.07 µg SC-560 
(relatively COX-1-specific inhibitor). This concentration of amfenac (40 µM) was 
empirically chosen using the rat model of OIR; the concentrations of celecoxib 
and SC-560 were matched to this concentration, to standardize treatment. 
Because amfenac does not possess the tissue-penetration characteristics of its 
pro-drug, nepafenac, and because celecoxib and SC-560 are not topically 
formulated, they were delivered directly to the target tissue with a single 
intravitreal injection. Oxygen-exposed rats received a single intravitreal injection 
of amfenac, celecoxib, or SC-560 on P14 and were sacrificed on P20. Amfenac 
significantly (p < 0.005) reduced the mean area of pre-retinal NV, compared to 
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vehicle-treated eyes (Figure 5). Celecoxib and SC-560 failed to inhibit OIR-
induced retinal NV at the doses tested. 
 
Effect of OIR on retinal prostanoids with and without amfenac 
Amfenac effectively inhibited NV in the rat OIR model, in contrast to 
celecoxib and SC-560. Thus, we sought to determine, more specifically, the 
way(s) in which the bioactive metabolite of nepafenac, amfenac, inhibited 
pathological angiogenesis. The effects of the OIR model and amfenac treatment 
on retinal prostanoid levels were surveyed. On P14, oxygen-exposed rats 
received a single intravitreal injection of vehicle or amfenac (0.05 µg; 40 µM). 
Figure 5. The effect of intravitreally-injected amfenac (40 µM), celecoxib, and SC-560 on the 
severity of OIR in the rat. Amfenac significantly reduced (* p < 0.005) OIR-induced retinal NV, 
but neither celecoxib nor SC-560 demonstrated an effect at the concentrations tested. Each 
bar represents the mean ± SEM. 
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One day later, on P15, the retinas were harvested and retinal prostanoid levels 
were measured. Compared to room air control retinas, the retinas of oxygen-
exposed rats demonstrated increased levels of each of the five prostanoids. 
Intravitreal amfenac treatment significantly reduced levels of PGE2, PGF2, TxB2, 
and 6-keto-PGF (p < 0.001) (Figure 6). This data demonstrates that amfenac 
inhibits COX and prostanoid production as expected, suggesting a possible 
explanation for the observed anti-angiogenic effect of amfenac in Figure 5. 
Figure 6.  The effect of OIR and amfenac on retinal prostanoid levels. Compared to room air 
control retinas, the retinas of OIR rats demonstrated increased levels of each of the five 
prostanoids. Intravitreal amfenac treatment (40 µM) significantly reduced levels of PGE2, PGF2, 
TxB2, and 6-keto-PGF (* p < 0.001) in OIR rat retinas. Each bar represents the mean ± SD. 
 
 
Effect of amfenac on rat Müller cell VEGF expression 
Since amfenac decreased retinal prostanoid levels and reduced NV in oxygen-
exposed rats, the effect of amfenac on specific angiogenic cell behaviors was 
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studied using in vitro methods. In order to determine whether or not amfenac 
inhibited hypoxia-induced VEGF production, rat Müller cells were treated with 
increasing doses of amfenac (0.1 to 10 µM), and placed in hypoxia for 24 hours. 
Quantitative RT-PCR analysis of VEGF revealed that amfenac exhibited no effect 
on hypoxia-induced VEGF mRNA expression in rat Müller cells (Figure 7). 
Figure 7. The effect of amfenac on hypoxia-induced VEGF expression in Müller cells. 
Quantitative RT-PCR analysis of VEGF revealed that amfenac exhibited no effect on hypoxia-
induced VEGF mRNA expression in rat retinal Müller cells. Each bar represents the mean ± SD. 
 
 
Effect of NSAIDs on VEGF and PGE2 production in rat Müller cells 
It is important to note that a change in VEGF mRNA does not always 
correlate with a change in VEGF protein (Wang FE, et al. IOVS 2004;45:ARVO 
E-Abstract 3711). Because the production, secretion, and turnover of VEGF 
protein directly contributes to the pathology observed in the rat OIR model, we 
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determined the effect of amfenac treatment on VEGF protein in hypoxic rat 
Müller cells. Rat Müller cells were treated with 1 µM amfenac, celecoxib, or SC-
560 and placed in hypoxia for 24 hours. Amfenac, celecoxib, and SC-560 had no 
Figure 8. The effect of amfenac, celecoxib, and SC-560 on Müller cell production of VEGF 
and PGE2. (A) 1 µM amfenac, celecoxib, and SC-560 had no effect on hypoxia-induced 
VEGF production in rat retinal Müller cells. (B) However, amfenac, celecoxib, and SC-560 
treatment significantly reduced PGE2 levels in these cells (* p < 0.001). This finding suggests 
that SC-560, at this concentration, is non-selective, inhibiting COX-2 as well as COX-1. Each 
bar represents the mean ± SD. 
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significant effect on hypoxia-induced VEGF production in rat Müller cells (Figure 
8A). However, amfenac, celecoxib, and SC-560 treatment profoundly and 
significantly reduced PGE2 levels in these cells (p < 0.001), implying that 
hypoxia-induced VEGF expression in rat Müller cells is not affected by 
pharmacologic manipulation of the COX-2 enzyme (Figure 8B). Since inhibition 
of COX did not reduce pro-angiogenic VEGF production in rat Müller cells, it 
cannot explain the inhibition of retinal NV by amfenac. 
 
Effect of amfenac on retinal VEGF production 
To complement our in vitro data (Figure 8A), we returned to the OIR 
model in order to determine whether amfenac inhibited retina-wide, as opposed 
to Müller cell-derived, VEGF production. Amfenac (0.05 µg; 40 µM) was 
administered by a single intravitreal injection to oxygen-exposed rats upon return 
to room air. Two days later, retinas were harvested and retinal VEGF levels were 
measured. As expected, oxygen-exposed rats experienced a 4-fold increase in 
retinal VEGF compared to room air controls (Figure 9). However, and in 
agreement with our in vitro findings, amfenac treatment demonstrated no 
significant effect on retinal VEGF in oxygen-exposed rats. Although a modest 
(20%) reduction in mean VEGF level was observed following amfenac treatment, 
this result was not statistically significant. Retinal VEGF levels following topical 
nepafenac treatment were also assayed to determine whether the natural in vivo 
metabolism of amfenac was required in order to achieve a VEGF response, and 
again no effect was observed (data not shown). 
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Effect of amfenac on VEGF-induced HRMEC behaviors 
Because nepafenac proved ineffective in preliminary in vitro assays, we 
used its bioactive metabolite, amfenac, to determine the effect of the drug on 
angiogenic endothelial cell behaviors. The effects of amfenac, celecoxib and SC-
560 on VEGF-induced tube formation and proliferation were examined. VEGF-
induced (25 ng/ml) HRMEC tube formation (as determined by mean tube length) 
was significantly inhibited by amfenac (p < 0.001), the COX-2-selective celecoxib 
(* p < 0.001; † p < 0.006), and, at higher concentrations, the relatively COX-1 
selective SC-560 (* p < 0.001; ‡ p < 0.01) (Figure 10). Amfenac also lead to a 
significant reduction (32.5%; 10.00 + 2.12 in VEGF-treated HRMEC vs. 6.75 + 
2.45 in 0.01 µM amfenac-treated HRMEC) in the number of HRMEC branch 
points in this assay (p < 0.0233; data not shown). VEGF-induced HRMEC 
proliferation was significantly inhibited by amfenac and celecoxib (p < 0.001, 
Figure 9. The effect of intravitreally-injected amfenac on retinal VEGF production. In 
agreement with the in vitro findings, 40 µM amfenac treatment demonstrated no significant 
effect on retinal VEGF levels in OIR rats. Each bar represents the mean ± SEM. 
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respectively) in a dose-dependent manner, whereas SC-560 (p < 0.001) was only 
inhibitory  at the highest concentration tested (Figure 11). Although 10 µM SC-
560 significantly inhibited VEGF-induced HRMEC proliferation, this concentration 
is known to inhibit both COX-1 and COX-2, and to exert COX-independent 
Figure 10.  The effect of amfenac, celecoxib, and SC-560 on VEGF-induced HRMEC tube 
formation. (A) HRMEC tube formation was induced by 25 ng/ml VEGF, and this induction was 
significantly inhibited by amfenac (* p < 0.001), the COX-2-selective NSAID celecoxib (* p < 
0.001; † p < 0.006), and, at higher concentrations, the COX-1 selective NSAID SC-560 (* p < 
0.001; ‡ p < 0.01). Each bar represents the mean ± SD. (B) A representative image of tube 
formation in VEGF-stimulated HRMEC. (C) A representative image of tube formation in 
VEGF-stimulated HRMEC treated with 1 µM amfenac. Amfenac-treated HRMEC demonstrate 
reduced tube formation. 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effects. These experiments suggest that amfenac, likely through COX inhibition, 
affects discrete aspects of the angiogenic cascade downstream of VEGFR-2 
activation. 
 
Topical nepafenac efficacy in rat OIR 
Topical administration of a drug that has the capacity to substantially 
reduce retinal NV would be a promising advancement in the development of 
therapies for neovascular eye diseases. Thus, we tested the capacity of topical 
Figure 11. The effect of amfenac, celecoxib, and SC-560 on VEGF-induced HRMEC 
proliferation. VEGF-induced HRMEC proliferation was significantly inhibited by amfenac 
and celecoxib (* p < 0.001) in a dose-dependent manner, and by SC-560 (* p < 0.001) at 
the highest concentration tested. The effect of SC-560 at the highest concentration may be 
attributed to lethality. Each bar represents the mean ± SD. 
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nepafenac to inhibit retinal NV in the rat model of OIR. Oxygen-exposed rats 
were treated with topical nepafenac four times daily (QID) or twice daily (BID) 
from P14 through P19 and were sacrificed on P20. Nepafenac (0.1%) delivered 
QID or BID significantly reduced (p < 0.001) the amount of pre-retinal NV in an 
apparent dose-dependent manner (Figure 12). Like nepafenac, ketorolac and 
diclofenac are labeled for the treatment of pain and inflammation following 
cataract surgery. We compared the effect of topical nepafenac (0.1%, QID) to 
these commercially available, topically formulated NSAIDs, ketorolac (0.5%, QID) 
and diclofenac (0.1%, QID), on OIR-induced retinal NV. Nepafenac significantly 
reduced the mean area of pre-retinal NV by 59.3% (p < 0.007), but neither 
ketorolac nor diclofenac demonstrated an effect at the tested doses (Figure 13).  
 
Figure 12. The effect of topical nepafenac on the severity of OIR in the rat. 0.1% nepafenac, 
given QID or BID from P14-P19, significantly reduced (* p < 0.001) OIR-induced retinal NV. 
Each bar represents the mean ± SEM. 
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Figure 13. The effect of topical nepafenac, ketorolac, and diclofenac on the severity of OIR in 
the rat. (A) Drugs were administered topically, QID, from P14-P19. Nepafenac significantly 
reduced (* p < 0.007) OIR-induced retinal NV. Ketorolac and diclofenac failed to demonstrate 
an effect. Each bar represents the mean ± SEM. (B) A representative image of NV in vehicle-
treated eyes. (C) A representative image of NV in nepafenac-treated eyes. As demonstrated 
by representative ADPase-stained retinal flat mounts, nepafenac significantly reduced retinal 
NV.  
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2.5 Discussion 
 
The goal of this study was two-fold. First, we used three in vitro assays to 
determine the capacity of amfenac to inhibit discrete aspects of retinal 
angiogenesis. Using these model systems, we were better able to determine 
where in the angiogenic cascade COX isoforms exert their influence. Second, in 
order to further investigate the therapeutic potential of nepafenac as an 
angiostatic agent for human ocular use, we tested the efficacy of nepafenac in 
vivo, using the rat model of OIR developed in our laboratory.  
In 2005, the FDA approved nepafenac for the treatment of pain and 
inflammation associated with cataract surgery (136-139). In the eye, nepafenac 
is converted to an active metabolite, amfenac, which like nepafenac is a 
reversible inhibitor of both COX-1 and COX-2, but unlike nepafenac has unique 
time-dependent inhibitory properties for both COX-1 and COX-2 (Kulmacz RJ, et 
al. 2007: EVER E-Abstract e473). Thus, we wanted to determine if, and more 
specifically how, amfenac inhibited pathological angiogenesis. Amfenac inhibits 
COX activity and COX-dependent prostanoid production. The cancer literature 
has shown that COX-2 and the prostanoids are involved in the angiogenesis that 
occurs during tumor growth (69-73). Moreover, recent studies have shown that 
COX inhibitors, including topical nepafenac, ameliorate various experimental 
pathologies in the posterior segment of the eye (77,111,112,138,141,148-151). 
We tested the hypothesis that amfenac, by virtue of its capacity to inhibit COX 
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activity, would inhibit pathological angiogenesis. This was done using three 
NSAIDs with varying selectivities for COX-1 and COX-2. Amfenac is a relatively 
non-selective NSAID, inhibiting both COX-1 (IC50 = 0.25 µM) and COX-2 (IC50 = 
0.15 µM) (137). Celecoxib is highly COX-2-selective (COX-2 IC50 = 0.06 µM, 
COX-1 IC50 = 19 µM) (152). SC-560 is relatively COX-1-selective (COX-1 IC50 = 
0.009 µM, COX-2 IC50 = 6.3 µM) (153). Only amfenac inhibited NV in the rat OIR 
model (Figure 5). 
It is possible that amfenac demonstrates superior ocular pharmacokinetics 
and bioavailability, and/or pharmacodynamic mechanisms than do celecoxib and 
SC-560. Or, amfenac may exert distinct COX-independent effects that mediate 
its angiostatic activity. The non-selective nature of amfenac’s COX inhibition may 
be one possible pharmacodynamic explanation for its superior performance. The 
importance of inhibiting both COX isoforms during ischemia-induced retinal NV 
has been suggested by results from studies using COX-1 null and COX-2 null 
mice (154). Due to its superior performance, we wanted to determine, more 
specifically, the way(s) in which amfenac inhibited pathological angiogenesis. We 
surveyed the effects of the oxygen exposure model and amfenac treatment on 
retinal prostanoid levels (Figure 6). All five of the prostanoids exhibited at least a 
two-fold increase upon exposure to the OIR protocol, suggesting a potential role 
in the development of retinal NV. The observed increase in retinal prostanoid 
production in oxygen-exposed rats could be due to: (1) increased cPLA2 level or 
activity, which serves to liberate arachidonic acid, the substrate that is converted 
by COX into prostanoids; (2) increased level or activity of COX-2; (3) increased 
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prostanoid synthase activity; (4) decreased levels of 15-PGDH, which is the key 
enzyme responsible for the biological inactivation of the prostanoids; or (5) some 
combination of these. Regardless of the mechanism by which prostanoids were 
increased, intravitreal injection of amfenac significantly inhibited the response. 
Retinal NV can be studied in vitro by distilling it into two basic 
components: hypoxia-induced VEGF production by retinal, e.g. Müller, cells and 
VEGF-induced angiogenic behaviors (proliferation and tube formation) in 
endothelial cells. We tested the capacity of amfenac to inhibit each of these 
processes in vitro so that we could more clearly define its mechanism of action in 
vivo. Amfenac had no effect on hypoxia-induced VEGF expression or production 
by rat Müller cells (Figure 7 and Figure 8A). This was confirmed in vivo: 
amfenac did not significantly decrease retinal VEGF levels in OIR rats (Figure 9). 
These data suggest that amfenac likely does not inhibit retinal NV in the rat 
model of OIR by reducing hypoxia-induced VEGF production. In accordance with 
our findings, Kern et al. reported that topically applied nepafenac did not reduce 
the increased retinal VEGF production found in diabetic rats (141). These results 
suggest that VEGF inhibition is unlikely to be a major contribution to amfenac’s 
anti-angiogenic activity. Our results contradict those of Takahashi et al. who 
showed that topical nepafenac reduced retinal VEGF mRNA in mice exposed to 
the OIR model (77). The discrepancy between our findings and Takahashi et al.’s 
findings may be due to: (1) inherent differences between the rat and mouse 
models of OIR; (2) inherent differences between the two species; or (3) the fact 
that Takahashi et al. looked at VEGF mRNA, whereas we looked at protein. It is 
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important to note that a change in VEGF mRNA does not always correlate with a 
change in VEGF protein (Wang FE, et al. IOVS 2004;45:ARVO E-Abstract 3711). 
Because the production, secretion, and turnover of VEGF protein directly 
contributes to the pathology observed in the rat OIR model, we chose this 
endpoint. Point number two brings up an important distinction, because it calls 
into question the universal capacity of NSAIDs to affect VEGF production.  
Since amfenac, a potent COX inhibitor, had no effect on VEGF production 
in vitro or in vivo, it is unlikely that pharmacologic manipulation of COX-2 affects 
this process. We tested this hypothesis using three different NSAIDs with varying 
selectivities for COX-1 and COX-2. The NSAID concentrations used in vitro were 
chosen because they fall within the range that allows us to distinguish between 
COX-1 and COX-2 effects. Amfenac, celecoxib, and SC-560 significantly 
inhibited Müller cell PGE2 production (Figure 8B), indicating that they did, in fact, 
inhibit COX activity in our cultures. However, the drugs had no effect on hypoxia-
induced VEGF production. This demonstrates that hypoxia-induced VEGF 
production by Müller cells is not diminished by pharmacologic inhibition of the 
COX-2 enzyme, and that the inhibition of pro-angiogenic VEGF production by 
Müller cells does not appear to be the mechanism by which amfenac inhibits 
retinal NV. It is possible that COX-dependent prostanoid production may 
influence VEGF production by other retinal cell types [as Amrite et al. have 
shown in retinal pigment epithelial (RPE) cells] (155), although our in vivo studies 
suggest that this is not the case in the rat model of OIR (Figure 9). Therefore, 
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COX inhibition by NSAIDs likely influences hypoxia-induced angiogenic cell 
behavior and OIR by a bioactivity unrelated to VEGF induction. 
Although we chose to focus on VEGF, it is possible that COX-dependent 
prostanoid production influences the production of angiogenic factors other than 
VEGF. Cheng et al. demonstrated that PGE2 induces bFGF expression in 
cultured rat Müller cells (75). Others have demonstrated that a different 
prostanoid, PGF2, induces bFGF expression in rat osteoblasts and endometrial 
adenocarcinoma explants (156,157). These and other studies demonstrate that 
there are other angiogenic factors whose production may be prostanoid-
dependent, and thus inhibited by amfenac treatment. We did not assess 
amfenac’s effect on these proteins [namely bFGF, the VEGF receptors, 
erythropoietin (EPO), adenosine, or insulin-like growth factor (IGF)]. Instead, we 
chose to look at the effect of amfenac on VEGF-stimulated angiogenic 
endothelial events because: (1) despite the presence and potential involvement 
of other, prostanoid-dependent angiogenic factors in the retina, none have been 
demonstrated to be both necessary and sufficient for the development of retinal 
NV, as VEGF has; (2) we see increases in VEGF in our model of OIR, but do not 
see increases in bFGF (158); and (3) HRMEC are exposed and respond to 
VEGF in human ROP, making it an appropriate means by which to stimulate and 
manipulate (with amfenac) angiogenic endothelial cell behaviors in vitro.  
Next, we sought to determine whether the effect of amfenac on retinal NV 
was being mediated through the inhibition of VEGF-induced angiogenic 
behaviors in endothelial cells. VEGF binds and activates high affinity VEGF 
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receptors on retinal endothelial cells (159). Binding of VEGF to VEGFR-2 
induces receptor dimerization and tyrosine autophosphorylation, activating 
complex and incompletely-defined signaling cascades (159). These signal 
transduction pathways ultimately lead to the induction of various endothelial 
behaviors necessary for angiogenesis, including proliferation, migration, survival, 
and the production of nitric oxide that leads to increased permeability. We tested 
the effect of amfenac, celecoxib, and SC-560 on two of these VEGF-induced 
behaviors: tube formation and proliferation. Amfenac and celecoxib dose-
dependently inhibited both VEGF-induced behaviors. These findings confirm 
those of Wu et al. who reported that HUVEC demonstrated reduced VEGF-
induced proliferation and tube formation when they were treated with NS-398 (a 
COX-2-selective inhibitor) or with siRNA directed against COX-2 (89). In our 
studies, the relatively-specific COX-1 inhibitor SC-560 was only mildly effective 
against tube formation alone (Figure 10 and Figure 11). Notably, 10 µM SC-560 
significantly inhibited VEGF-induced HRMEC proliferation. This concentration of 
SC-560 inhibits COX-2 (in addition to inhibiting the COX-1 target enzyme) and 
exerts COX-independent effects on HRMEC proliferation, suggesting an 
explanation for its dramatic effect. Notably, amfenac inhibited two measures of 
tube formation, mean tube length and the number of HRMEC branch points 
(Figure 10). The effect of COX-2 inhibition on endothelial cell branching has 
been documented in the literature, and was confirmed by our study (89). 
Amfenac, likely through inhibition of COX-2, affects discrete aspects of the 
angiogenic cascade downstream of VEGFR-2 activation. It is known that VEGF-
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stimulated endothelial cells produce PGs (160). It is also known that PGs 
stimulate proliferation and tube formation, therefore demonstrating angiogenic 
effects (86,161). Our data suggests that the capacity of nepafenac to inhibit 
proliferation and tube formation is dependent on its capacity to inhibit pro-
angiogenic PG production by COX-2. This in vitro data suggests that nepafenac’s 
mechanism of action in ROP is dependent on its capacity to inhibit endothelial 
cell bioactivities like proliferation and tube formation, two behaviors that are 
central to the development of pathological ocular NV in ROP.  
Safe and effective anti-angiogenic therapies that can be delivered 
noninvasively remain an unmet need in ophthalmology. Lucentis®, an anti-VEGF 
antibody fragment (Fab) delivered via intravitreal injection, is the current 
standard-of-care for neovascular age-related macular degeneration (AMD). 
During multiple registration studies, intravitreal injections of Lucentis® stabilized 
vision in over 90% of patients, and improved vision in up to 40% of patients. 
However, repeated intravitreal injections were necessary for the majority of 
patients to maintain this level of benefit (162-166). Intravitreal injections require 
an office visit, are often expensive, can be physically uncomfortable, and they 
expose the patient to a number of potential vision-threatening complications such 
as intraocular infection. Topical administration of a drug that has the capacity to 
substantially reduce retinal NV would be a promising advancement in the 
development of therapies for neovascular eye diseases. Nepafenac, topically 
applied to the cornea two or four times daily, significantly inhibited the 
development of retinal NV in the rat model of OIR (Figure 12). This finding is 
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consistent with those of Takahashi et al. who reported that topical nepafenac 
inhibited ischemia-induced retinal NV in mice (77). We hypothesized that the 
anti-angiogenic effect of nepafenac was due to its capacity to inhibit COX and 
pro-angiogenic prostanoid production. However, it was unexpected that 
nepafenac proved to be unique in its capacity to significantly inhibit oxygen-
induced retinal NV; ketorolac and diclofenac demonstrated no significant effect 
(Figure 13). This observation cannot be explained by the COX-2 selectivities of 
the three compounds, because their respective COX-2 IC50’s are within the same 
range: amfenac = 0.15 µM, ketorolac = 0.086 µM, and diclofenac = 0.038 µM 
(137,167). A more plausible explanation is that topical nepafenac likely has 
superior bioavailability to the posterior segment. In early pre-clinical trials, 
nepafenac exhibited superior corneal penetration and suppressed prostanoid 
production by the iris/cilliary body and retina/choroid more efficiently and for a 
longer duration than did diclofenac (136,137). In rabbits, topical administration of 
0.1% nepafenac  lead to nanomolar concentrations of amfenac in both anterior 
and posterior segment tissues, above the COX-2 IC50, indicating sufficient 
penetration for inhibitory activity (Hariprasad SM, et al. IOVS 2009:50:ARVO E-
Abstract 5999). Topical administration of nepafenac provided highest 
concentrations in the sclera > choroid > retina > vitreous. Pharmacologically 
relevant concentrations in the posterior segment were achieved through a 
scleral/choroidal distribution. Together, these data suggest that prostanoid 
synthesis is an important aspect of oxygen-induced retinal NV and that 
nepafenac’s inhibitory effect on retinal NV is due, at least in part, to its capacity to 
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efficiently penetrate the cornea/sclera and inhibit COX-dependent prostanoid 
synthesis in the retina. 
The findings that HRMEC treated with amfenac and celecoxib 
demonstrate reduced VEGF-induced tube formation and proliferation suggest 
that there are COX-2-dependent mechanisms through which amfenac inhibits 
oxygen-induced retinal NV. Amfenac and celecoxib may also inhibit VEGF-
induced angiogenic cell behaviors through COX-2-independent mechanisms. For 
example, Amrite et al. reported that choroidal endothelial cells treated with 
celecoxib demonstrated reduced proliferation, but that the anti-proliferative effect 
of celecoxib was independent of its COX-2-inhibitory action (168). Nepafenac 
appears to be a rational therapeutic strategy for the non-invasive treatment of 
oxygen-induced retinopathies and other neovascular diseases of the eye, and it 
appears that nepafenac’s mechanism of action is dependent on its capacity to 
inhibit endothelial cell bioactivities like proliferation and tube formation, two 
behaviors that are central to the development of pathological ocular NV.  
Evidence suggests that oxidative compounds play a role in ROP and other 
angiogenic diseases of the retina (141,169-171). The retina is particularly 
susceptible to oxidative damage because it has a high rate of oxygen 
consumption (172). Furthermore, premature infants have an incompletely 
developed antioxidant system, leading to a reduced ability to scavenge reactive 
oxidative species (ROS) (173). This may increase their vulnerability to the effects 
of damaging oxidative species. These findings have led to a large body of basic 
and clinical research focused on understanding the effect of antioxidant 
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supplementation in ROP. A meta-analysis of clinical studies that tested the effect 
of vitamin E supplementation on the incidence and severity of ROP development 
demonstrated that vitamin E supplementation led to a 52% reduction in the 
development of stage 3 ROP (characterized by NV) (174). Vitamin E, superoxide 
dismutase, and apocynin (an NADPH oxidase inhibitor) have all been shown to 
prevent the development of pathological features that present in the rat model of 
ROP (175-178). More recently, Kern et al. have shown that nepafenac 
demonstrates anti-oxidant activity (141). Nepafenac inhibited diabetes-induced 
production of superoxide anion (a ROS) in rat retinas. It is known that ROS 
activates cytosolic phospholipase A2 (cPLA2) and COX-2, which can lead to the 
production of potentially pro-angiogenic PGs (179,180). cPLA2 is the enzyme 
responsible for liberating arachidonic acid, a COX substrate, from membrane-
derived phospholipids. cPLA2 has been shown to have a pro-angiogenic effect 
on retinal cell behaviors (109). These may be additional mechanisms of 
nepafenac’s action: it may prevent the ROS-dependent activation of cPLA2 
and/or COX-2 and the resultant PG-induced angiogenic cell behaviors. Although 
we did not assess nepafenac’s anti-oxidant capacity in our model of ROP, it is 
feasible that a portion of nepafenac’s mechanism of action may have been 
related to its capacity to scavenge damaging ROS. 
Various stimuli, including COX-derived PGs, stimulate endothelial nitric 
oxide synthase (eNOS) (181). Stimulation of eNOS leads to the production of 
nitric oxide (NO), a potent signaling molecule. NO plays a role in maintaining 
blood flow and vascular tone. Increased NO production leads to vasodilation, 
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which can be particularly harmful to the retinas of premature infants on oxygen 
therapy. In adults, retinal blood flow and choroidal blood flow are tightly 
regulated; when an adult retina is exposed to hyperoxia, retinal and choroidal 
blood vessels constrict, limiting excessive oxygen delivery to the retina.  This 
vascular regulation is lacking in infants. Failure of the vasculature to constrict in 
response to high oxygen, coupled with the vaso-dilatory effect of high NO, means 
that the infant is particularly sensitive to the deleterious consequences of hyper-
oxygenation. This inability to limit oxygen delivery may contribute to the infant’s 
susceptibility to hyperoxia-induced ROP (182). These findings suggest that 
inhibiting COX-derived PG production will inhibit deleterious NO production, 
providing protection against hyperoxia-induced retinopathy. We have shown that 
amfenac inhibits PG production in vitro and in vivo  (Figure 6 and Figure 8). 
Although we did not assess nepafenac’s capacity to inhibit NO production in our 
model of ROP, it is possible that a portion of nepafenac’s mechanism of action 
may have been related to its capacity to prevent PG-mediated NO production 
and vasodilation. Notably, NO inhibition may also be detrimental to premature 
infants on supplemental oxygen therapy. eNOS and NO  are required for the 
development of normal lung vasculature. MacRitchie et al. have shown that there 
is reduced eNOS in the pulmonary circulation and respiratory tract of preterm 
lambs on oxygen therapy and suggest that reduced eNOS may play a role in the 
development of chronic lung disease in the lambs (183). Furthermore, eNOS 
deficient mice exhibit defective lung vascular development and respiratory 
distress (184). Therefore, if it is found that nepafenac inhibits NO production and 
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has a beneficial effect on the ocular vasculature in models of ROP, it’s effect on 
the pulmonary vasculature will need to be carefully assessed in clinical trials.   
Pharmacologic inhibition of COX-2 did not have a major effect on hypoxia-
induced VEGF production in our models. Despite pharmacologic inhibition, 
residual COX activity may have remained, which could continue to produce pro-
angiogenic prostanoids with the capacity to affect VEGF production (75,76). 
Alternatively, Lukiw et al. reported that hypoxia-induced VEGF production was 
directly regulated by HIF-1, and only indirectly regulated through NF-κB-
mediated COX-2 in choroidal endothelial cells (185). This suggests that HIF-1-
dependent VEGF production may have the capacity to overpower the effect of 
COX-2-inhibition, and could explain the results of our Müller cell studies. In order 
to more clearly define the role of COX-2 in this process, it is necessary to assess 
VEGF production in COX-2 knock-out animals and the cells derived from these 
animals. These studies are on going. 
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3.1 Abstract 
 
Non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX 
activity, reduce the production of retinal VEGF and neovascularization in relevant 
models of ocular disease. We hypothesized that COX-2 mediates VEGF 
production in retinal Müller cells, one of its primary sources in retinal neovascular 
disease. The purpose of this study was to determine the role of COX-2 and its 
products in VEGF expression and secretion. These studies have more clearly 
defined the role of COX-2 and COX-2-derived prostanoids in retinal 
angiogenesis. 
Müller cells derived from wild-type and COX-2 null mice were exposed to 
hypoxia for 0-24 hours. COX-2 protein and activity were assessed by western 
blot analysis and GC-MS, respectively. VEGF production was assessed by 
ELISA. Wild-type mouse Müller cells were treated with vehicle (0.1% DMSO), 10 
µM PGE2, or PGE2 + 5 µM H-89 (a PKA inhibitor), for 12 hours. VEGF production 
was assessed by ELISA.  
Hypoxia significantly increased COX-2 protein (p < 0.05) and activity (p < 
0.05), and VEGF production (p < 0.0003). COX-2 null Müller cells produced 
significantly less VEGF in response to hypoxia (p < 0.05). Of the prostanoids, 
PGE2 was significantly increased by hypoxia (p < 0.02). Exogenous PGE2 
significantly increased VEGF production by Müller cells (p < 0.0039), and this 
effect was inhibited by H-89 (p < 0.055). 
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These data demonstrate that hypoxia induces COX-2, prostanoid 
production, and VEGF synthesis in Müller cells, and that VEGF production is at 
least partially COX-2-dependent. Our study suggests that PGE2, signaling 
through the EP2 and/or EP4 receptor and PKA, mediates the VEGF response of 
Müller cells.  
 
3.2 Introduction 
 
Angiogenesis, the formation of new capillaries from the existing 
vasculature, is a process subject to exquisite regulation. Numerous pathological 
conditions are characterized by persistent, abnormal angiogenesis. In the eye, 
pathological angiogenesis, or ocular neovascularization (NV), is the leading 
cause of blindness in developed countries (9,10,12). Prevalent diseases in which 
ocular NV is a central feature include retinopathy of prematurity (ROP), 
proliferative diabetic retinopathy (PDR), and age-related macular degeneration 
(AMD or ARMD). To effectively prevent and treat ocular NV, a more thorough 
understanding of the cellular and molecular mechanisms involved in the 
angiogenic process is necessary.  
Neovascularization within the eye is often the result of ischemia, which 
induces tissue hypoxia (114,115). In response to retinal hypoxia, various pro-
angiogenic growth factors are produced, each mediating a number of angiogenic 
cell behaviors. Of the growth factors involved in retinal angiogenesis, vascular 
endothelial cell growth factor (VEGF) is thought to be a principal mediator (22). In 
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response to retinal hypoxia, several cell types exhibit increased VEGF production 
(32,33,116). This has been demonstrated most consistently and dramatically in 
Müller cells, the predominant glial cells within the retina (32-34). Notably, Müller 
cell-specific deletion of VEGF-A significantly inhibits NV in mice exposed to 
oxygen-induced retinopathy (186). 
The cyclooxygenase (COX) enzymes are responsible for catalyzing the 
production of biologically active prostanoids (prostaglandins and thromboxanes) 
from phospholipid-derived arachidonic acid. The cancer literature has 
demonstrated a role for COX-2, the inducible isoform, and its prostanoid 
metabolites in the angiogenesis that occurs during tumor growth (69-73). 
Prostanoids can induce the expression of pro-angiogenic factors such as VEGF 
and bFGF in a wide variety of cell types (75,76). 
COX-2 has been localized to various ocular tissues, and its expression 
has been found, or can be induced, in the following structures: cornea, iris, 
cilliary body, various cell types within the neuroretina, and the retinal pigment 
epithelium (RPE) (95,97-100). The expression of the COX-2 enzyme in these 
ocular tissues suggests a functional role for its prostanoid products. In fact, 
inhibition of COX has been effective at reducing the production of VEGF and 
corneal, retinal, and choroidal NV in relevant models of ocular disease 
(84,107,110-113,187-189). However, although various groups have 
demonstrated the efficacy of COX inhibition at reducing the production of VEGF 
and NV, little work has been done to determine which of the COX-2 derived 
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prostanoid(s) is (are) involved in mediating VEGF production, which stimulates 
angiogenic endothelial cell behaviors, and results in ocular angiogenesis. 
In this study, we used an in vitro assay of hypoxia-induced VEGF 
production combined with cells isolated from COX-2 null mice to more precisely 
determine the role of COX-2 and its products in stimulating mouse Müller cell 
VEGF production. These studies are important because VEGF is the growth 
factor that stimulates the pathological angiogenesis characteristic of ROP, PDR, 
AMD, and a number of other blinding conditions. These studies have further 
defined the roles of COX-2 and COX-2-derived prostanoids in this discrete 
aspect of retinal angiogenesis. 
 
3.3 Materials and Methods 
 
Isolation and culture of primary mouse Müller cells  
Primary Müller cell cultures were established from P7 wild-type C57/129 
mouse pups and COX-2 null mouse pups on the same background (breeders 
were a generous gift from Dr. Sudhansu Dey, Cincinnati Children’s Hospital 
Medical Center), according to well-established methods (144). Briefly, enucleated 
eyes were placed in soaking medium, Dulbecco’s Modified Eagle Medium 
(DMEM; HyClone) supplemented with 1X Antibiotic/Antimycotic Solution (Sigma), 
overnight. The following day, eyes were incubated in digestion buffer, which is 
comprised of soaking medium plus 0.1% trypsin and 70 U/ml collagenase, for 20 
minutes at 37ºC. Retinas were then dissected, triturated, plated, and grown in 
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DMEM supplemented with 10% fetal bovine serum and 1X Antibiotic/Antimycotic 
Solution. Cultures were maintained at 37ºC in a 5% CO2/95% air (20.9% oxygen) 
atmosphere (normoxia) in a humidified incubator (NuAire). The identification of 
Müller cells was confirmed by immunocytochemical staining with a monoclonal 
antibody against vimentin (Affinity Bioreagents; Golden, CO), an intermediate 
filament protein normally expressed in Müller cells, and with a monoclonal 
antibody against cellular retinaldehyde binding protein (CRALBP; Affinity 
Bioreagents). Passages three to six were used for experiments. Normoxic and 
hypoxic conditions (< 1.0% oxygen) were generated with an Isotemp 3-gas 
Laboratory CO2 Incubator with O2 control (Kendro Laboratory Products; 
Asheville, NC) and a Proox Model 110 Gas Oxygen Controller (BioSpherix; 
Lacona, NY). Appropriate humidity and 5% CO2 were maintained. 
 
Western blot analysis  
Wild-type and COX-2 null mouse Müller cells at 70% subconfluency were 
exposed to hypoxia for 0, 2, 6, 12, 18, or 24 hours. The lysates were matched for 
protein concentration, and proteins were resolved by 10% SDS-PAGE minigels 
(Bio-Rad; Hercules, CA) and transferred to 0.2 µM nitrocellulose membranes 
(Bio-Rad). Membranes were blocked in TBS containing 0.1% Tween-20 (Sigma) 
and 1% BSA (Sigma) overnight at 4ºC. The blots were incubated with antibodies 
recognizing COX-1 and COX-2 (Cayman) for one hour, followed by an anti-rabbit 
IgG HRP antibody (Promega) for 45 minutes, at room temperature. Following 
thorough washings, the proteins were visualized with enhanced 
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chemiluminiscence (ECL; Amersham; Piscataway, NJ). Membranes were 
stripped and reprobed for β-actin (Sigma). Digitized images of Western blots 
were quantified using Image J software (NIH). Raw densitometric values were 
normalized against internal control (β-actin). 
 
Müller cell prostanoid measurement 
Wild-type mouse Müller cells at 70% subconfluency were treated with 
0.5% serum medium and exposed to either normoxia or hypoxia for 0, 2, 6, 12, 
18, or 24 hours. Conditioned medium was collected and the lipid soluble 
prostanoids were reverse-phase, solid-phase extracted using Sep-Pak C18 
columns (Waters) and nitrogen-evaporated. O-methoxyamine derivatives were 
formed by treatment with 2% methoxyamine-HCl in water at room temperature 
for 30 minutes. Compounds were extracted with ethyl acetate and subsequently 
converted to pentaflurobenzyl esters. The compounds were chromatographed on 
TLC plates with ethyl acetate/methanol. The compounds were then converted to 
trimethylsilyl ether derivatives and analyzed by negative ion chemical ionization 
mass spectrometry coupled with a gas chromatography system (Agilent 
Technologies). The amount of each prostanoid (ng/ml) in culture medium was 
normalized to total protein concentration (mg/ml) of cell lysates using a BCA 
assay (Pierce). Thus, any variation in prostanoid production due to differences in 
cell densities was resolved. 
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Hypoxic induction of VEGF in Müller cells  
Wild-type and COX-2 null mouse Müller cells at 70% subconfluency were 
exposed to hypoxia for 0, 2, 6, 12, 18, or 24 hours. Culture medium from 
experimental dishes was collected and assayed for VEGF protein concentration 
with a colorimetric sandwich ELISA kit (R&D Systems) according to the 
manufacturer’s instructions. The assay recognizes the 164 amino acid residue 
splice variant of mouse VEGF. Cells were washed with cold calcium- and 
magnesium-free PBS (Invitrogen) and lysed with cold lysis buffer (Promega). The 
amount of VEGF (pg/ml) in culture medium was normalized to total protein 
concentration (mg/ml) of cell lysates using a BCA assay (Pierce). Thus, any 
variation in VEGF production due to differences in cell densities was resolved. 
 
PGE2 and H-89 treatment of Müller cells 
Wild-type mouse Müller cells at 70% subconfluency were serum-starved 
for 6 hours, and then pre-treated with 5 μM H-89 (Cayman Chemical) for 1 hour. 
Following pre-treatment, the cells received fresh serum-free medium with H-89, 
and were treated with 10 μM PGE2 (dinoprostone; Cayman Chemical) for 12 
hours. Culture medium from experimental dishes was collected and assayed for 
VEGF protein concentration as described above. 
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Statistical analysis 
Data were analyzed with commercial software (JMP; SAS Institute). 
Analysis of variance (ANOVA) with Dunnet’s post-hoc analyses and t tests were 
used to analyze parametric data.  
 
3.4 Results 
 
Effect of hypoxia on COX-2 protein and activity 
Wild-type mouse Müller cells exposed to hypoxia showed increased levels 
of the COX-2 protein (Figure 14). The densitometry of the COX-2 bands 
(normalized against the densitometry of the β-actin bands) was quantified, and 
demonstrated that COX-2 was maximally and significantly (p < 0.05) induced 6 
and 12 hours after hypoxic treatment. Müller cells isolated from COX-2 null mice 
lack COX-2, as demonstrated by western blot analysis (Appendix 1). COX-1 is 
the isoform of COX classically recognized as being constitutively active (65). 
Importantly, hypoxia did not lead to increased COX-1 in wild-type cells (Figure 
14). Nor did hypoxia stimulate COX-1 in COX-2 null cells, indicating that COX-1 
was not compensating for the absence of the COX-2 enzyme (Figure 14). Due to 
the fact that COX-2 is an enzyme, an increase in the level of the protein does not 
necessarily indicate that activity is increased. In order to assess COX-2 activity, 
we assessed the concentration of PGE2 in the conditioned medium from hypoxia-
treated cells. We chose to look at PGE2 as a surrogate marker of COX-2 activity 
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because COX-2-derived PGE2 is the prostanoid product most consistently 
upregulated in angiogenic tumor models (190). Consistent with an increase in 
COX-2 protein, COX-2 activity, as demonstrated by increased PGE2 production, 
is likewise significantly increased (* p < 0.02; † p < 0.05; ‡  p < 0.05) by hypoxia 
(Figure 15).  
 
Figure 14. The effect of hypoxia on COX-1 and COX-2 in mouse Müller cells. Wild-type 
mouse Müller cells demonstrated an increase in COX-2 upon exposure to hypoxia. Neither 
wild-type nor COX-2 null mouse Müller cells demonstrated an increase in COX-1 upon 
exposure to hypoxia. Additionally, COX-1 did not appear to be compensating for genetic 
deletion of the COX-2 gene in null cells. 
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Effect of hypoxia on VEGF production 
We have previously demonstrated the effect of hypoxia on Müller cell 
production of VEGF (191). We chose to look at a time course of VEGF production 
by hypoxic Müller cells because we hypothesized that COX-2-derived 
prostanoids mediate VEGF production in these cells, and we wanted to 
empirically determine the time course, and therefore likelihood, of these events 
being mechanistically linked. VEGF levels were significantly (p < 0.0003) 
increased over time in hypoxia, peaking at 24 hours (Figure 16). Hypoxic 
Figure 15. The effect of hypoxia on COX-2 activity in wild-type mouse Müller cells. 
Consistent with increased COX-2 protein, COX-2 activity was likewise significantly increased 
(* p < 0.01; † p < 0.025; ‡ p < 0.05) by hypoxia, as determined by the production of COX-2-
derived PGE2. Each bar represents mean + SD. 
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treatment lasting longer than 24 hours led to cell death, and hence, later time 
points were not examined. 
 
Effect of COX-2 deletion on VEGF protein 
In order to determine the COX-2-dependent effect on hypoxia-induced 
VEGF production by mouse Müller cells, we cultured wild-type and COX-2 null 
mouse Müller cells, exposed them to hypoxia for increasing periods of time, and 
assessed VEGF level. VEGF production was reduced in hypoxic COX-2 null 
cells, compared to wild-type cells, at every time point. This effect was statistically 
significant (p < 0.05) after 12, 18, and 24 hours of hypoxic treatment (Figure 17). 
Figure 16. The effect of hypoxia on wild-type mouse Müller cell production of VEGF. Hypoxia 
significantly increased VEGF production in wild-type mouse Müller cells (* p < 0.0003), with a 
time course that lagged behind that of hypoxia-induced COX-2 protein and activity, 
suggesting that some degree of VEGF production may be stimulated by COX-2-derived 
prostanoids. Each bar represents mean + SD. 
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These data demonstrate that VEGF production by mouse Müller cells is at least 
partially dependent on COX-2 and COX-2-derived bioactive prostanoids.  
 
Effect of hypoxia on prostanoid production 
In order to more clearly define which of the prostanoids might have been 
influencing hypoxic VEGF production, we analyzed prostanoid production in cells 
that had been maintained in normoxia and hypoxia for 24 hours. We chose to 
examine prostanoid production at this time point because the cells remained 
viable and demonstrated maximal VEGF production. Hypoxic treatment 
significantly increased (p < 0.02) levels of PGE2. Although levels of PGF2, PGI2, 
Figure 17. The effect of COX-2 deletion on VEGF protein. VEGF production was reduced in 
hypoxia-treated COX-2 null cells, compared to wild-type cells, at every time point.  This effect 
was statistically significant (* p < 0.05) after 12, 18, and 24 hours of hypoxic treatment, 
indicating that VEGF production is partially COX-2-dependent. Each bar represents mean + 
SD. 
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and TXA2 also were increased by hypoxia, the results were not statistically 
significant (Figure 18). We performed the same survey in COX-2 null Müller 
cells, and as expected, baseline (normoxia) prostanoid production was 
dramatically reduced and the cells failed to demonstrate any hypoxia-reactivity 
(data not shown). These data demonstrate that several of the prostanoids are 
increased in the wild-type response to hypoxia, and suggest that PGE2, 
particularly, may play an important role in VEGF production by hypoxic mouse 
Müller cells. 
 
 
Figure 18. The effect of hypoxia on prostanoid production by wild-type mouse Müller cells. 
Twenty four hours of hypoxia led to significantly increased (* p < 0.02) levels of PGE2. 
Although levels of PGF2, PGI2, and TXA2 were increased by hypoxia, the results were not 
significant. Each bar represents mean + SD. 
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Effect of PGE2 and PKA inhibitor H-89 on prostanoid production 
In order to more clearly define the role of COX-2-derived PGE2 on VEGF 
production, Müller cells were treated with PGE2 and their ability to produce VEGF 
was assessed (Figure 19). We chose to use wild-type cells because the COX-2 
null cells do not produce measurable quantities of VEGF following overnight 
serum-starvation and subsequent treatment with a low serum concentration, as 
required in this assay. We chose to use PGE2 (10 µM dinoprostone) because our 
GC-MS data (Figure 18) indicated that this prostanoid was significantly 
increased by hypoxia. We chose to treat the cells for 12 hours because there 
Figure 19. The effect of PGE2 and PKA inhibition on VEGF production by wild-type mouse 
Müller cells. Twelve hours of PGE2 (10 µM) treatment significantly (* p < 0.0039) increased 
VEGF production by Müller cells. The PGE2-induced increase in VEGF was completely 
inhibited († p < 0.0055) by treatment with 5 µM H-89, a PKA inhibitor. These data suggest 
that the effect of PGE2 on VEGF induction is mediated by the EP2 and/or EP4 receptors. Each 
bar represents mean + SD. 
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was a 6-12 hour lag time between maximal COX-2 induction and maximal VEGF 
production, and we believe that these two events are mechanistically linked and 
that 12 hours may be needed for COX-2 and the prostanoids to affect the VEGF 
transcription and translation machinery. Dinoprostone significantly (* p < 0.0039) 
increased VEGF production. The PGE2-induced increase in VEGF was 
completely inhibited († p < 0.0055) by treatment with the PKA inhibitor H-89. 
These data suggest that the effect of PGE2 on VEGF induction is mediated by 
the EP2 and/or EP4 receptors, receptors known to signal through the PKA 
pathway (192). 
 
3.5 Discussion 
 
Recent studies indicate that inhibiting the COX enzymes is an effective 
means by which to inhibit VEGF production and NV in relevant models of ocular 
disease (107,110-13,187-189). COX inhibitors have demonstrated efficacy in 
corneal, retinal, and choroidal models of angiogenesis. Although these studies 
have demonstrated the efficacy of COX inhibition at reducing the production of 
VEGF and NV, little work has been done to determine the mechanism by which 
COX-2 and its prostanoid products mediate VEGF production and the resultant 
ocular angiogenesis. In this study, we used an in vitro assay of hypoxia-induced 
VEGF production to examine the role of COX-2 and the prostanoids in mediating 
VEGF production by mouse retinal Müller cells, the cells that most consistently 
and dramatically increase production of VEGF in response to angiogenic 
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stimulation, as a necessary first step in the process of defining a more specific 
therapeutic target in the treatment of retinal NV (32-34,186).  
It is well known that retinal ischemia-induced hypoxia is one driving force 
behind retinal NV (114,115). It is also known that hypoxic challenge induces 
COX-2 in various cell types, including vascular endothelial cells, corneal 
epithelial cells, and various tumor cell lines (83,193-197). We looked at the COX-
2 response of mouse Müller cells exposed to hypoxia for increasing periods of 
time. In response to hypoxia, wild-type mouse Müller cells demonstrated 
significantly increased levels of COX-2 and prostanoid production (Figures 14, 
15 and 18). These data agree with the findings of others (referenced above) and 
were expected, COX-2 is an immediate early gene, rapidly and transiently 
induced by a variety of stimuli (198). Herein, we have also shown that wild-type 
mouse Müller cells demonstrated significantly increased levels of VEGF in 
response to hypoxia (Figure 16), and VEGF levels were increased with a 
temporal sequence that lagged behind COX-2 induction and activity. The time 
sequence of VEGF production by hypoxic mouse Müller cells is consistent with 
the hypothesis that there are COX-2-dependent aspects of VEGF production.  
Previous studies have demonstrated that COX-2 is involved in mediating 
growth factor production in various cell types, and in response to various stimuli 
(75,76). The present study has shown that COX-2 was upregulated and activated 
by hypoxia, and VEGF levels were increased, in an in vitro assay of hypoxia-
induced VEGF production. We have also shown that, compared to wild-type 
cells, COX-2 null mouse Müller cells treated with hypoxia produce significantly 
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less VEGF (Figure 17). This finding suggests that COX-2 and its prostanoid 
products play a role in the VEGF response of Müller cells. These data agree with 
the findings of others; researchers studying angiogenesis related to various 
cancers and other neovascularizing conditions have demonstrated, using 
pharmacologic and genetic manipulation of COX-2, that COX-2 inhibition resulted 
in reduced VEGF production, in vitro and in vivo (77-80). Of more relevance to 
the eye, NSAID use has been effective at reducing the production of VEGF and 
NV in relevant models of ocular disease (107,110-113,154,187-189). Our findings 
have important implications for conditions characterized by retinal NV. Retinal 
hypoxia leads to increased production of VEGF, and VEGF is thought to be a 
principal mediator of the angiogenesis that occurs in retinal NV (22). The Müller 
cells most consistently and dramatically increase production of VEGF in 
response to retinal hypoxia (32-34,186). We have shown that genetic deletion of 
COX-2 and the resultant reduction in prostanoid synthesis led to a significant 
reduction in hypoxia-induced VEGF production by Müller cells. However, COX-2 
activity leads to the production of five bioactive prostanoid products. Thus, our 
results led us to investigate which of the prostanoids were involved in VEGF 
production by mouse Müller cells, in order to define a more selective 
chemotherapeutic target for the treatment and management of retinal NV. 
COX-2 activity results in the formation of five biologically active 
prostanoids (PGD2, PGE2, PGF2, PGI2, TXA2). In response to hypoxia, wild-type 
mouse Müller cells demonstrated significantly increased levels of PGE2 (Figure 
18), suggesting that this prostanoid might play a role in mediating VEGF 
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production. In fact, treating Müller cells with PGE2 significantly increased VEGF 
production (Figure 19). Of relevance to our focus, Cheng et al., using pure, 
primary cultures of rat Müller cells, demonstrated that PGE2 significantly induced 
VEGF mRNA, with maximal VEGF mRNA noted 2 hours post-prostaglandin 
treatment (75). Our PGE2 data confirms what has been shown in the literature – 
that PGE2 stimulates VEGF production in widely diverse cell types (132,199-
203). PGE2 affects a wide range of physiological and pathological processes by 
binding to distinct cell surface G-protein-coupled receptors (GPCRs). PGE2 binds 
and activates one (or more) prostaglandin E (EP) receptors: EP1, EP2, EP3, and 
EP4 (67). The receptors demonstrate distinct, as well as opposing, effects on 
intracellular signaling events. Of these receptors, EP2 and EP4 couple to Gs and 
mediate a rise in cAMP concentration and subsequent PKA activity. We chose to 
focus our attention on these receptors because Müller cells derived from EP1 and 
EP3 null mice failed to inhibit hypoxia-induced VEGF production by Müller cells 
(Appendix 2). There have been numerous reports in the literature demonstrating 
a role of these two receptors in mediating PGE2-induced angiogenic cell 
behaviors (132,199-201). We sought to determine whether this was the case in 
our model system. Of particular interest, in our model system, hypoxia led to a 
2.5-fold increase in PKA activity (data not shown). As shown in Figure 19, the 
PKA inhibitor virtually abolished PGE2-induced VEGF production in mouse Müller 
cells. These findings agree with a large body of published findings (75,204-1206). 
Our data suggests that PGE2 signals through the EP2 and/or EP4 receptor(s), 
activating PKA, which ultimately leads to VEGF production by Müller cells.  
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Although we have focused our attention on PGE2 and its cognate 
receptors, it is possible that one or more of the other prostanoids, specifically 
PGI2 or PGF2, both of which were stimulated by hypoxia (Figure 18), play a role 
in mediating retinal NV. These prostanoids signal through the IP and FP 
receptors, respectively. A review of these receptors implicates both of them in 
angiogenic cell behaviors and tumor progression (207). Additionally, the IP 
receptor is predominantly coupled to Gs, meaning that its activation leads to 
increased cAMP production and PKA activity. In the future, it will be important to 
determine whether all prostanoids that demonstrate pro-angiogenic activity in 
Müller cells signal through PKA, and affect VEGF production similarly. To more 
clearly define the specific role(s) of the EP2 and EP4 receptors, as well as the IP 
and FP receptors in retinal NV, we have planned studies using pharmacologic 
agents as well as genetically modified mice and cells derived from their retinas. 
Preliminary, non-optimized studies have shown that latanoprost, a PGF2 analog, 
significantly increased VEGF production by COX-2 null Müller cells (Appendix 
3). 
We have, for the first time, used COX-2 null mouse Müller cells to show 
that COX-2 and at least one of its prostanoid products, PGE2, is involved in 
VEGF production. Our study implicates PGE2, signaling through the EP2 and/or 
EP4 receptor(s), in mediating the VEGF response of the cells. Figure 20 depicts 
our working model, illustrating how COX-2 activation leads to VEGF production in 
these cells. This information may provide a more selective chemotherapeutic 
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target for the prevention and/or treatment of conditions in which retinal 
angiogenesis is a pathologic feature. 
 
 
 
 
 
Figure 20. A flowchart demonstrating the way that we hypothesize COX-2 mediates hypoxia-
induced VEGF production by Müller cells. In response to hypoxia, COX-2 is up-regulated, 
leading to increased production of pro-angiogenic PGE2. PGE2 binds to the EP2 and/or EP4 
receptors, activating G proteins that couple to increased cAMP production. cAMP activates 
PKA, which is involved in mediating VEGF production. 
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4.1 Abstract 
 
PGE2 binds to PGE2 receptors (EP1-4). The purpose of the present study 
was to investigate the role of the EP4 receptor in angiogenic cell behaviors of 
retinal Müller cells and retinal microvascular endothelial cells (RMEC), and to 
assess the efficacy of an EP4 antagonist in rat models of oxygen-induced 
retinopathy (OIR) and laser-induced choroidal neovascularization (LCNV). 
Müller cells derived from COX-2 null mice were treated with increasing 
concentrations of the EP4 agonist PGE1-OH and wild-type Müller cells were 
treated with increasing concentrations of the EP4 antagonist L-161982; VEGF 
production was assessed. Human RMEC (HRMEC) were treated with increasing 
concentrations of L-161982 and cell proliferation and tube formation were 
assessed.  Rats subjected to OIR or LCNV were administered L-161982 and 
neovascular area was measured.  
COX-2 null mouse Müller cells treated with increasing concentrations of 
PGE1-OH demonstrated a significant increase in VEGF production (p < 0.0165). 
Wild-type mouse Müller cells treated with increasing concentrations of L-161982 
demonstrated a significant decrease in VEGF production (p < 0.0291). HRMEC 
treated with increasing concentrations of L-161982 demonstrated a significant 
reduction in VEGF-induced cell proliferation (p < 0.0033) and tube formation (p < 
0.0344). L-161982 treatment significantly reduced pathological 
neovascularization in OIR (p < 0.0069) and LCNV (p < 0.0329).  
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Preliminary investigation has demonstrated that EP4 activation or inhibition 
influences the behaviors of two retinal cell types known to play roles in 
pathological ocular angiogenesis. These findings suggest that the EP4 receptor 
may be a valuable therapeutic target in neovascular eye disease. 
 
4.2 Introduction 
 
Angiogenesis, the formation of new capillaries from an existing 
vasculature, is a tightly regulated physiological process essential for 
reproduction, embryonic growth and development, and tissue repair and 
regeneration (1). In these circumstances, angiogenesis is strictly regulated and 
briefly activated.  Conversely, pathological processes, such as arthritis and 
tumorigenesis, are characterized by persistent, poorly regulated angiogenesis. In 
the eye, pathological angiogenesis, or ocular neovascularization (NV), is the 
leading cause of irreversible blindness in developed countries (9,10,12). Ocular 
NV is a defining feature of retinopathy of prematurity (ROP), proliferative diabetic 
retinopathy (PDR), and neovascular age-related macular degeneration (AMD or 
ARMD). To more effectively prevent and treat ocular NV, a thorough 
understanding of the cellular and molecular mechanisms involved is necessary. 
Retinal NV is often the result of ischemia-induced hypoxia (114,115). In 
response to retinal hypoxia, several cell types increase their production of pro-
angiogenic growth factors. Of the growth factors involved in retinal NV, vascular 
endothelial growth factor (VEGF) is recognized as the principal mediator of 
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ocular NV (32,55,116). Hypoxia-induced VEGF production has been 
demonstrated most consistently and dramatically in Müller cells, the predominant 
glial cells within the retina (32-34,186). Once VEGF is produced and secreted, it 
binds and activates two cell-surface receptor tyrosine kinases, VEGFR-1 (Flt-1) 
and VEGFR-2 (KDR/Flk-1), with high affinity (23). These receptors are expressed 
on the surface of endothelial cells. VEGFR-2 is the principle receptor involved in 
VEGF signal transduction leading to angiogenesis (49). VEGFR-2 activation 
initiates a number of signal transduction cascades leading to angiogenic 
endothelial cell behaviors such as survival, permeability, proliferation, and 
migration (23).  
The cyclooxygenase (COX) enzymes catalyze the biosynthesis of five 
biologically active prostanoids (prostaglandins and thromboxanes) from 
membrane-derived arachidonic acid.  The prostanoids include PGD2, PGE2, 
PGF2, PGI2, and TXA2. There is ample evidence of a role for COX-2, the 
inducible COX isoform, and its prostanoid metabolites, principally PGE2, in tumor 
angiogenesis (69-73).  
The prostanoids affect a wide range of physiological and pathological 
processes by binding to distinct cell surface G-protein-coupled receptors 
(GPCRs). PGE2 binds and activates one (or more) of four prostaglandin E (EP) 
receptors: EP1, EP2, EP3, and EP4 (67). The receptors demonstrate distinct, as 
well as opposing, effects on intracellular signaling events. The EP1 receptor 
couples to Gq and mediates a rise in intracellular calcium concentration. The EP2 
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and EP4 receptors couple to Gs and mediate a rise in cAMP concentration. In 
contrast, the EP3 receptor couples to Gi, reducing cAMP concentration.  
Various groups have determined a direct role for PGE2 and EP4 in 
angiogenic gene expression (199,208), angiogenic cell behaviors (209-215), and 
the angiogenic component of tumor growth (209,216-219). However, the majority 
of these studies have been conducted using in vitro and in vivo models of colon 
cancer.  It remains to be determined whether the EP4 receptor plays a similar 
role in ocular NV. 
In this study, in vitro experiments were performed to investigate the 
influence of the EP4 receptor on discrete aspects of retinal angiogenesis.  First, 
prostanoid-mediated VEGF production was assayed to investigate the role of the 
EP4 receptor in stimulating Müller cell VEGF production.  Second, the effect of 
EP4 receptor antagonism on VEGF-induced endothelial cell proliferation and tube 
formation was investigated in retinal microvascular endothelial cells (RMEC).  
Finally, to further investigate the therapeutic potential of EP4 receptor antagonism 
for human use, two clinically relevant in vivo models of ocular NV were used.  
Rat models of retinal and choroidal NV were used to assess the efficacy of EP4 
receptor antagonism. These studies will help to define the role of the EP4 
receptor in mediating pathological ocular angiogenesis. 
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4.3 Materials and Methods 
 
Isolation and culture of primary mouse retinal Müller cells   
Primary retinal Müller cell cultures were established from P7 wild-type and 
COX-2 null mice (a generous gift from Dr. Sudhansu Dey, Cincinnati Children’s 
Hospital Medical Center) according to well-established methods (144). Briefly, 
enucleated eyes were placed in soaking medium, Dulbecco’s Modified Eagle 
Medium Low Glucose (DMEM; HyClone) supplemented with 1X 
Antibiotic/Antimycotic Solution (Sigma), overnight.  The following day, eyes were 
incubated in digestion buffer, comprised of the soaking medium plus 0.1% trypsin 
and 70 U/ml collagenase, for 20 minutes at 37ºC.  Retinas were then dissected, 
triturated, plated, and grown in DMEM supplemented with 10% fetal bovine 
serum and 1X Antibiotic/Antimycotic Solution.  Cultures were maintained at 37ºC 
in a 5% CO2/95% air (20.9% oxygen) atmosphere (normoxia) in a humidified 
incubator (NuAire).  Passages three to six were used for experiments. 
 
Culture of human retinal microvascular endothelial cells (HRMEC)  
Human retinal microvascular endothelial cells (HRMEC; Cell Systems) 
were cultured in tissue flasks coated with attachment factor (Cell Signaling) in 
endothelial basal medium (EBM; Cambrex) supplemented with 10% FBS and 
EGM single quots (Cambrex). When experimental conditions required serum free 
(SF) medium, EBM with no FBS or single quots was used. Cultures were 
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maintained at 37ºC in a 5% CO2/95% air (20.9% oxygen) atmosphere (normoxia) 
in a humidified incubator. 
 
Müller cell VEGF induction 
Müller cells were isolated from wild-type and COX-2 null mice and grown 
to 70% sub-confluency. In one experiment, COX-2 null cells were serum-starved 
for 12 hours (DMEM supplemented with 1X Antibiotic/Antimycotic Solution) and 
then treated with vehicle (0.1% DMSO) or increasing concentrations (0.1 to 10 
µM) of the PGE2 EP4 agonist, PGE1-OH (Cayman Chemical), in 2% serum 
medium.  After 6 hours, culture medium from experimental dishes was collected 
and assayed for VEGF protein concentration. In a separate experiment, wild-type 
mouse Müller cells were serum-starved for 12 hours, and then pre-treated with 
vehicle (0.1% DMSO) or increasing concentrations (1 to 5 µM) of the EP4 
antagonist, L-161982, in 2% serum medium. Forty-five minutes later, the cells 
were treated with 10 µM PGE2 (Cayman Chemical). After 12 hours, culture 
medium from experimental dishes was collected and assayed for VEGF protein 
concentration. For both experiments, VEGF protein concentration was measured 
using the mouse VEGF-164 ELISA kit (R&D Systems) according to the 
manufacturer’s instructions.  Cells were washed with cold calcium- and 
magnesium-free PBS (Invitrogen Corporation) and lysed with cold lysis buffer 
(Promega). The amount of VEGF (pg/ml) in culture medium was normalized to 
total protein concentration (mg/ml) of cell lysates using a BCA assay (Pierce). 
These experiments were independently repeated two times. 
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HRMEC proliferation 
HRMEC were seeded in 10% serum EBM at 3x103 cells per well in a 96-
well plate, and allowed to attach and settle.  HRMEC were serum-starved for 12 
hours, and then treated with 1% serum medium in the absence or presence of 25 
ng/ml VEGF. Some of the cells treated with VEGF received increasing 
concentrations (1 to 5 µM) of L-161982, for 24 hours. Cells were then labeled 
with BrdU for 12 hours, and BrdU incorporation was quantified with a colorimetric 
ELISA (Roche; Indianapolis, IN) according to the manufacturer’s instructions. 
The experiment was independently repeated four times. 
 
HRMEC tube formation 
Six-well tissue culture plates were coated with 500 µL of growth factor-
reduced Matrigel (Becton-Dickinson). HRMEC were seeded at 40,000 cells/well 
and treated with serum-free EBM containing vehicle (0.1% DMSO) or 3, 5 or 10 
µM L-161982. The cells were cultured for 24 hours at 37ºC in a 5% CO2 
atmosphere. Tubes were observed with an IMT-2 inverted microscope 
(Olympus), and images were captured with a DMC digitizing camera (Polaroid 
Corporation). Six fields per well were captured for quantitative analysis. The 
digitized images were imported into Image J software (NIH). Capillary-like 
structures of more than two cell lengths were assessed, and the mean tube 
length per field of each well was calculated. The average tube length of each 
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treatment group was reported. The experiment was independently repeated three 
times. 
 
Oxygen-induced retinopathy (OIR) 
All animal procedures used in this study were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee and were performed in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. Litters of Sprague-Dawley rat pups and their mothers (Charles 
River Laboratories) were transferred within four hours after birth to oxygen 
exposure chambers where they received alternating 24 hour periods of 50% 
oxygen and 10% oxygen for 14 days (143). On post-natal day 14 (P14), the 
oxygen-exposed rats were returned to room air. Vehicle (0.1% DMSO) or the EP4 
antagonist, L-161982 (0.01, 0.1, and 0.7 µM), was administered to oxygen-
exposed rats at P14 by intravitreal injection, according to well-established 
methods (145). Six days after removal to room air, on P20, the rats were 
sacrificed, and their retinas dissected. Following dissection, the retinas were 
stained with ADPase, using well-established methods (171). Abnormal retinal 
neovascularization was measured via computer-assisted image analysis (145). 
 
Laser-induced choroidal neovascularization (LCNV) 
Laser-induced rupture of Bruch’s membrane was performed to produce 
CNV in 6-week-old, male Brown Norway rats, as previously described (220). 
Using a hand-held cover slip as a contact lens, an argon laser photocoagulator 
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(532 nm) mounted on a slit-lamp (Coherent Novus Omni) was employed to 
create four lesions in both the left and right eyes of each animal (50 µm spot size, 
0.1 second duration, 360 mW). The animals’ eyes were then divided into the 
following treatment groups [vehicle (0.1% DMSO); 0.01 µM L-161982; 0.1 µM L-
161982; 1 µM L-161982] and received an intravitreal injection at the temporal ora 
1, 3, and 7 days following laser treatment. Fourteen days after laser application, 
rats were sacrificed to measure the extent of CNV at the Bruch’s membrane 
rupture sites. Endothelial cells in CNV lesions were identified by staining RPE-
Bruch’s membrane-choroid flatmounts using FITC-conjugated isolectin B4 
(Sigma), and the elastin of the extracellular matrix was identified using an elastin 
antibody conjugated to Cy3 (Sigma). Areas of abnormal vascular growth were 
measured via computer-assisted image analysis using high-resolution digital 
images of the stained choroid-sclera-RPE flat-mounts. This experiment was 
independently repeated two times.  
 
Statistical analysis 
Data were analyzed with commercial software (JMP; SAS Institute). 
Analysis of variance (ANOVA) with appropriate post-hoc analyses were used to 
analyze data. 
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4.4 Results 
 
Effect of an EP4 agonist, PGE1-OH, on VEGF production 
To investigate the contribution of the PGE2 EP4 receptor to VEGF 
production, COX-2 null Müller cells were treated with increasing concentrations 
(0.1 to 10 µM) of PGE1-OH, an EP4 receptor agonist. Treatment lasted 6 hours. 
Agonism of the EP4 receptor significantly (* p < 0.0001; † p < 0.006; ‡ p < 
0.0165) increased VEGF production by COX-2 null Müller cells, in a dose-
dependent manner (Figure 21). 
Figure 21. The effect of an EP4 agonist, PGE1-OH, on VEGF production in COX-2 null 
mouse Müller cells. PGE1-OH significantly increased VEGF production by COX-2 null cells. 
Each bar represents the mean ± SD. * p < 0.0001; † p < 0.006; ‡ p < 0.0165 (Dunnet’s post-
hoc analysis). For each bar, n = 4. 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Effect of an EP4 antagonist, L-161982, on PGE2-induced VEGF production 
To further investigate the contribution of the PGE2 EP4 receptor to VEGF 
production, wild-type Müller cells were pre-treated with increasing concentrations 
(1 to 5 µM) of L-161982, an EP4 receptor antagonist, for 45 minutes, followed by 
10 µM PGE2 stimulation. Treatment lasted 12 hours. Antagonism of the EP4 
receptor significantly (* p < 0.0066; † p < 0.0291) decreased PGE2-induced 
VEGF production by wild-type Müller cells (Figure 22). 
 
Figure 22. The effect of an EP4 antagonist, L-161982, on PGE2-induced VEGF production by 
wild-type mouse Müller cells. L-161982 pre-treatment significantly decreased PGE2-induced 
VEGF production by wild-type mouse Müller cells. Each bar represents the mean ± SD. * p < 
0.0066; † p < 0.0291 (Dunnet’s post-hoc analysis). For each bar, n = 4. 
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Effect of an EP4 antagonist, L-161982, on VEGF-induced HRMEC 
proliferation 
To investigate the contribution of the EP4 receptor to VEGF-induced 
HRMEC proliferation, HRMEC were treated with VEGF and increasing 
concentrations (1 to 5 µM) of the EP4 receptor antagonist, L-161982. L-161982 
significantly (* p < 0.0001; † p < 0.0033) inhibited VEGF-induced cell proliferation 
in HRMEC (Figure 23). 
 
 
 
Figure 23. The effect of an EP4 antagonist, L-161982, on VEGF-induced HRMEC 
proliferation. HRMEC proliferation was stimulated with 25 ng/ml VEGF. L-161982 significantly 
decreased VEGF-induced cell proliferation in HRMEC. Each bar represents the mean ± SD. * 
p < 0.0001; † p < 0.0033 (Dunnet’s post-hoc analysis). For each bar, n = 11. 
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Effect of an EP4 antagonist, L-161982, on HRMEC tube formation 
To investigate the influence of the EP4 receptor on HRMEC tube 
formation, HRMEC were treated with increasing concentrations (3 to 10 µM) of 
the EP4 receptor antagonist, L-161982. L-161982 caused a dose-dependent 
decrease in HRMEC tube formation, and significantly (* p < 0.0344) inhibited 
tube formation at the highest dose tested (Figure 24 and 25). 
Figure 24. The effect of an EP4 antagonist, L-161982, on HRMEC tube formation. L-161982 
significantly decreased tube formation in a dose-dependent manner. Each bar represents the 
mean ± SD. * p < 0.0344 (Dunnet’s post-hoc analysis). For each bar, n = 3. 
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Effect of an EP4 antagonist, L-161982, on OIR in the rat 
Figures 21 through 25 demonstrate that EP4 activation or inhibition 
influences the behaviors of two retinal cell types that are known to play roles in 
the pathological ocular angiogenesis characteristic of neovascular retinopathies. 
Next, the efficacy of the EP4 antagonist L-161982 was tested in the rat model of 
OIR. At P14, OIR rats received either vehicle (0.1% DMSO) or L-161982 (0.01, 
Figure 25. The effect of an EP4 antagonist, L-161982, on HRMEC tube formation. L-161982 
(10 µM) significantly decreased tube formation, as depicted in representative 
photomicrographs. A. HRMEC treated with vehicle (0.1% DMSO); B. HRMEC treated with 10 
µM L-161982. 
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0.1, or 0.7 µM) by intravitreal injection. Six days post-injection, the retinas were 
dissected, flat-mounted, stained, and assessed for extent of neovascularization 
via computer-assisted image analysis. As shown in Figures 26 and 27, EP4 
receptor antagonism significantly [0.769 ± 0.141 (0.7 µM) * p < 0.0001; 1.088 ± 
0.210 (0.1 µM) † p < 0.001; 1.267 ± 0.175 (0.01 µM) ‡ p < 0.0069 vs. 2.126 ± 
.204 mm2 (vehicle-treated)] inhibited the severity of neovascularization in the OIR 
model. 
Figure 26. The effect of an EP4 antagonist, L-161982, on the severity of oxygen-induced 
retinopathy in the rat. L-161982 significantly decreased the severity of OIR in a dose-dependent 
manner. Each bar represents the mean ± SEM. * p < 0.0001; † p < 0.001; ‡ p < 0.0069 (Dunnet’s 
post-hoc analysis). For vehicle, n = 9; 0.01 and 0.1 µM, n= 10; 0.7 µM, n = 11. 
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Effect of an EP4 antagonist, L-161982, on the severity of LCNV in the rat 
The efficacy of L-161982 was tested in a second model of ocular 
neovascularization, the rat model of LCNV. Rats received intravitreal injections of 
vehicle (0.1% DMSO) or 0.01, 0.1, or 1 µM L-161982 on days 1, 3, and 7 
following laser treatment. Rats were sacrificed 14 days post-laser treatment. 
Analysis of stained flatmounts demonstrated that L-161982 significantly [172.666 
± 18.068 (drug-treated) vs. 257.133 ± 12.472 µm2 (vehicle-treated); * p < 0.0329] 
reduced the severity of the LCNV response at the highest concentration tested (1 
Figure 27. The effect of an EP4 antagonist, L-161982, on the severity of oxygen-induced 
retinopathy in the rat, as visualized by representative ADPase-stained retinal flat mounts. L-
161982 significantly decreased the severity of OIR. A. Eye treated with vehicle (0.1% 
DMSO); B. Eye treated with 0.7 µM L-161982. 
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µM), as indicated by a reduced area of choroidal endothelial cell infiltration at the 
lesion site (Figures 28 and 29).                                                          
 
4.5 Discussion 
 
The COX-2 enzyme leads to the production of five bioactive lipids 
(prostanoids) that mediate diverse physiological and pathophysiological 
processes. Of the prostanoids, PGE2 is most consistently increased in 
angiogenic human tumors (69-73). We have demonstrated that PGE2 is 
Figure 28. The effect of an EP4 antagonist, L-161982, on the severity of laser-induced 
choroidal neovascularization in the rat. The highest concentration of L-161982 significantly 
decreased the severity of LCNV. Each bar represents the mean ± SEM. * p < 0.0329 
(Fisher’s LSD post-hoc analysis). For vehicle and 1 µM, n = 16; 0.01 µM, n = 28; 0.1 µM, n = 
24. 
  93 
increased in in vitro experiments that model retinal angiogenic cell behaviors, 
and in in vivo models of retinal angiogenesis (data not shown). Preliminary 
studies conducted in our lab suggest that the effect of PGE2 on retinal 
angiogenesis is mediated by the EP4 receptor. This hypothesis is based on the 
following preliminary findings: 1) Müller cells derived from EP1 and EP3 knockout 
Figure 29. The effect of an EP4 antagonist, L-161982, on the severity of laser-induced 
choroidal neovascularization in the rat, as visualized by isolectin B4 (green) and elastin (red) 
stained RPE-Bruch’s membrane-choroid flat mounts. The highest concentration of L-161982 
was able to significantly decrease the severity of LCNV, as indicated by decreased choroidal 
endothelial cell infiltration around the laser-induced wound site. A. Eye treated with vehicle 
(0.1% DMSO); B. Eye treated with 1 µM L-161982. 
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mice fail to inhibit angiogenic cell behavior, as measured by hypoxia-induced 
VEGF production (Appendix 2); and 2) specific agonists of EP1-3 fail to elicit a 
VEGF response in COX-2 knockout Müller cells. To our knowledge, this study is 
the first to examine and demonstrate a role for the EP4 receptor in retinal 
angiogenesis.  
Müller cells derived from COX-2 null mice exhibit reduced VEGF 
production (Yanni SE, et al. IOVS 2007;48:ARVO E-Abstract 51), presumably 
due to the absence of COX-2 and pro-angiogenic prostanoid production. We 
have demonstrated that VEGF can be stimulated in COX-2 null Müller cells by 
the EP4 agonist PGE1-OH (Figure 21). Compared to wild-type cells, COX-2 null 
cells in culture do not demonstrate any significant difference in the protein level 
of EP4 (data not shown). This suggests that the results in Figure 21 are not due 
to EP4 compensation in COX-2 null cells. We have also demonstrated that PGE2-
induced VEGF can be inhibited by the EP4 receptor antagonist, L-161982 
(Figure 22). To our knowledge, this study is the first to use primary cultures of 
Müller cells derived from COX-2-deficient mice. Our Müller cell data compliments 
a growing body of data in the literature: various cell types and model systems 
have been used to demonstrate that VEGF production is at least partially 
dependent on the EP4 receptor (199,201,216,221,222). We have also 
demonstrated that HRMEC treated with the EP4 antagonist L-161982 exhibit 
reduced VEGF-induced cell proliferation and tube formation (Figures 23 – 25). 
Notably, L-161982 significantly inhibits HRMEC proliferation at a concentration 
lower than that required to inhibit HRMEC tube formation. Under our assay 
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conditions, tube formation requires little, if any, cell proliferation. The finding that 
L-161982 more effectively inhibits HRMEC proliferation than tube formation 
suggests that the EP4 receptor differentially regulates angiogenic endothelial cell 
behaviors, exerting a much stronger influence on proliferation than migration. 
The fact that only the highest concentration (10 µM) of L-161982 demonstrated 
an effect on HRMEC tube formation suggests that the EP4 receptor might not 
play an important role in vascular reorganization (as modeled by this assay), but 
may play a more important role in sprouting angiogenesis. Additional 
experiments could be used to corroborate the role of EP4 in sprouting 
angiogenesis in vitro. Additionally, in order to more clearly define the activity of L-
161982, it will be necessary to explore the signal intermediates affected by drug 
treatment. Our HRMEC data also complement the literature, which demonstrates 
that in other cell types, the EP4 receptor is involved in ERK activation, cell 
proliferation, and angiogenic cell behavior (211,213,214). Ideally, the 
investigators would have liked to assess the effect of EP4 agonism in VEGF-
induced HRMEC assays (proliferation and tube formation). The appropriate way 
to perform this experiment is in the absence of endogenous prostaglandin 
production and influence. Therefore, cells isolated from COX-2 null mice are the 
optimal experimental venue. Unfortunately, this approach is not possible for the 
following reasons: in culture, COX-2 null mouse RMEC (MRMEC) lose their EC 
phenotype, and do not survive passaging, rendering them useless in in vitro 
assays of the type required. After unsuccessfully trying this approach, the 
authors investigated siRNA knockdown of COX-2 in HRMEC, in order to use 
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knockdown cells for agonist studies. However, only 60% knockdown was 
obtained, despite trying several siRNA sequences alone and in combination. In 
these cases, enough residual COX-2 activity remained to confound the results 
obtained using knockdown cells treated with the EP4 agonist. In the future, it will 
be of great value to attempt to isolate MRMEC from COX-2+/- mice (cells that 
have less COX-2 protein than wild-type cells), followed by siRNA knockdown of 
residual COX-2. This experimental approach may yield MRMEC lacking COX-2 
activity, which can be used in the assays described above. Alternatively, other 
means of achieving stable knockdown should be explored. 
These experiments indicate that the EP4 receptor mediates distinct 
angiogenic cell behaviors in two retinal cell types that are known to play roles in 
the pathological ocular angiogenesis characteristic of neovascular retinopathies. 
This finding is significant because it suggests that EP4 receptor inhibition has the 
potential to affect the ocular angiogenic cascade at more than one point, 
providing a more powerful and effective therapeutic target for angiogenic 
diseases of the eye and other tissues. 
As an initial step in determining therapeutic potential, we tested the 
efficacy of the EP4 antagonist L-161982 in rat models of OIR and LCNV and have 
shown that this compound reduced the severity of neovascularization in both 
model systems (Figures 26 – 29). In both models, L-161982 was injected into 
the vitreous cavity. Thus, L-161982 may be more bioavailable at sites of pre-
retinal NV than at sites of sub-retinal NV, explaining the drug’s superior 
performance in OIR vs. LCNV. L-161982, at high concentrations, binds and 
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activates the angiotensin II AT1 receptor, which has angiogenic activity (223). Of 
particular relevance, the angiogenic activity of the AT1 receptor has been 
demonstrated in a mouse model of oxygen-induced retinopathy (224,225). 
Additionally, L-161982 has the following Ki values for other prostanoid receptors 
(in µM): 0.024 for EP4, 0.71 for TP, 1.90 for EP3, 5.10 for DP, 5.63 for FP, 6.74 
for IP, 19 for EP1 and 23 for EP2. Some of these receptors have demonstrated 
angiogenic activity, as detailed in the literature (207). Thus, the in vivo 
concentrations chosen should be selective for EP4. For this reason, we chose to 
inject low concentrations of L-161982 in the OIR and LCNV models. In order to 
complement the data presented herein, and to more clearly define the specific 
role(s) of the EP4 receptor in ocular neovascularization, without the confound of 
AT1 receptor activation, studies using EP4 null cells and animals are currently 
underway. Preliminary data suggests that the pharmacologic data presented 
here will be validated by studies using genetically modified mice and cells 
derived from their retinas. 
Various models of in vivo angiogenesis and tumor growth have similarly 
demonstrated the EP4 receptor to be pro-angiogenic, and that EP4 receptor 
inhibition elicits an anti-angiogenic effect (209,214,216,218,219). The data 
presented here suggest that the EP4 receptor exerts its angiogenic influence by 
promoting VEGF production by Müller cells and that antagonism of the receptor 
inhibits VEGF production by Müller cells and endothelial cell proliferation and 
tube formation. These novel findings suggest that EP4 receptor antagonism may 
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be a rational therapeutic strategy for the treatment of human neovascular eye 
disease. 
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CHAPTER V 
 
CONCLUDING REMARKS 
 
COX-2 and the prostanoids are up-regulated in many types of human 
cancers (70,226-228). These findings implicate these proteins in the 
angiogenesis that occurs as a part of the disease process. In fact, COX-2 
inhibition has proven to be an effective means by which to inhibit tumor growth in 
animal models of disease (69,229-231). In large part due to data derived from 
coxib-treated animals, there have been several hundred clinical trials designed to 
assess the efficacy of COX-2 inhibitors, alone or as a therapeutic adjuvant, on 
the regression of human tumors. Unfortunately, many of the human clinical trials 
using COX-2 inhibitors were suspended because of the occurrence of adverse 
cardiovascular effects (232,233). Broad inhibition of COX-2 and all five of the 
downstream prostanoids appears to be a therapeutic strategy of limited clinical 
utility. This is likely because the prostanoids mediate a wide variety of 
physiological, as well as pathophysiological, processes. Selectively inhibiting one 
component of the COX-2 enzymatic cascade (e.g., one of the five prostanoids, or 
one of the nine receptors) may provide a more rational approach, one that is 
safer and more tolerable, but remains highly effective. 
In the eye, various groups have demonstrated that COX inhibitors reduced 
the severity of pathological ocular angiogenesis in animal models 
(77,95,107,108,110-113,189). However, little work has been done to determine 
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which of the COX-2-derived prostanoid(s) is (are) involved in mediating VEGF 
production, downstream angiogenic endothelial cell behaviors, and ocular 
angiogenesis. Because of this gap in ocular angiogenesis research, we 
examined the specific involvement of COX-2, COX-2-derived prostanoids, and 
prostanoid receptors in ocular angiogenesis. The goal of our research was two-
fold. We wanted to: 1) better understand the role of COX-2-derived prostanoids 
in ocular angiogenic disease, and 2) use the knowledge gained through our 
research to identify more specific therapeutic targets. 
In order to better understand ocular angiogenesis, we typically distill it into 
its two most basic components: growth factor production by Müller cells, and 
growth factor consumption by (and stimulation of angiogenic cell behaviors in) 
endothelial cells. Surprisingly, NSAID-treated Müller cells did not demonstrate 
reduced hypoxia-induced VEGF production (Figure 8A). This finding contrasted 
with a body of scientific data, collected from a variety of cell types, which 
demonstrated the capacity of NSAIDs to inhibit pro-angiogenic VEGF production 
(79,155,234-236). However, COX-2 is an enzyme, and therefore despite NSAID 
treatment, it is likely that residual COX-2 activity remained, which stimulated 
prostanoid production, and resulted in VEGF induction. In order to address this 
possibility, we isolated Müller cells derived from COX-2 and prostanoid receptor 
knockout animals. We showed that genetic deletion of COX-2 significantly 
reduced hypoxia-induced VEGF production (Figure 17), the principal growth 
factor responsible for the development of retinal NV. Furthermore, and more 
specifically, we showed that of the COX-2-derived prostanoids, PGE2 was 
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significantly increased in response to hypoxia (Figure 18), and a stable analog of 
PGE2 stimulated VEGF production by Müller cells (Figure 19). This finding 
complements that of Cheng et al., who demonstrated that PGE2 stimulated an 
increase in VEGF mRNA in cultured rat Müller cells (75). It is also likely that one 
of the other COX-2-derived prostanoids, specifically PGF2 or PGI2, both of which 
were increased by hypoxia, participates in VEGF production by Müller cells. In 
order to address this question unequivocally, future experiments should be 
designed using COX-2 null cells and stable analogs of each of the prostanoids, 
alone and in combination. Preliminary, non-optimized studies have shown that 
latanoprost, a PGF2 analog, significantly increased VEGF production by COX-2 
null Müller cells (Appendix 3). This finding suggests that the FP receptor may 
constitute a rational therapeutic target in neovascular eye disease, either alone 
or in combination with other prostanoid receptors. This experiment, and a 
complementary experiment using a PGI2 analog, must be optimized and 
repeated. Studies are underway to determine the effects of FP and IP 
antagonism on hypoxia-induced VEGF production by Müller cells.  
Our Müller cell data motivates a complementary set of experiments to be 
performed downstream, in endothelial cells. Specifically, it is of importance to 
understand: which prostanoids are increased by VEGF-treatment of RMEC; do 
RMEC increase production of the same prostanoids as Müller cells, under 
relevant treatment conditions (i.e., VEGF treatment); does genetic deletion of 
COX-2 affect VEGF-induced RMEC angiogenic cell behaviors (survival, 
proliferation, migration, permeability); does one prostanoid, or several in 
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combination, rescue the phenotype (if there is one) of COX-2 null RMEC? The 
most ideal venue for many of the experiments listed above is COX-2 null RMEC. 
While we have successfully isolated these cells, we have been unsuccessful in 
our attempts to amplify them, or with achieving adequate knockdown with siRNA. 
Future efforts should be spent optimizing one of these two methodologies. It will 
be of great value to attempt to isolate MRMEC from COX-2+/- mice (cells that 
have less COX-2 protein than wild-type cells), followed by siRNA knockdown of 
residual COX-2. This experimental approach may yield MRMEC lacking COX-2 
activity, which can be used in endothelial cell assays. Alternatively, other means 
of achieving stable knockdown in RMEC should be explored. Stable analogs of 
PGF2 and PGI2, as well as inhibitors of FP and IP, are currently being assessed 
in angiogenic endothelial cell assays. Once these experiments have been 
completed, the vision research community will have a more thorough 
understanding of the role of COX-2 in endothelial cell angiogenic behaviors. This 
information, in conjunction with the Müller cell data, will facilitate our 
understanding of the molecular basis of ocular angiogenic disease, as well as the 
development of a more specific therapeutic target, or combination of targets. 
As a first step towards understanding the mechanisms of, and developing 
a novel therapeutic target for, ocular angiogenic diseases, we demonstrated that 
EP4 receptor antagonism significantly inhibited angiogenic cell behaviors in two 
retinal cell types that are known to play roles in the pathological ocular 
angiogenesis characteristic of neovascular retinopathies. Specifically, EP4 
receptor antagonism inhibited Müller cell production of VEGF and endothelial cell 
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proliferation and tube formation. Additionally, antagonism of the EP4 receptor in 
vivo significantly inhibited NV associated with both OIR and LCNV (Chapter IV). 
It is important to mention that although we did achieve significant inhibition of NV 
with the EP4 antagonist, its therapeutic effect was much less dramatic than that 
of other compounds tested in the lab. In fact, intravitreal injection of an EP4 
receptor antagonist was less effective than topical administration of a broad COX 
inhibitor, in our model of OIR (Figures 12 and 26). This finding suggests that: 1) 
the COX inhibitor may have exerted COX-independent anti-angiogenic effects; 
and/or 2) the EP4 receptor is not the sole prostanoid receptor with a role in this 
pathology. Thus, additional experiments should be designed to ascertain 
precisely which prostanoids are increased in VEGF-treated endothelial cells and 
their specific roles in angiogenic endothelial cell behaviors (as described above), 
compared to the prostanoids involved in Müller cell angiogenic activity, and then 
a list of prostanoid receptors with potential involvement both up- and downstream 
of VEGF production can be generated. The results of those studies might 
suggest that targeting a different prostanoid or prostanoid receptor, alone or in 
combination with EP4, will provide enhanced therapeutic efficacy, which is the 
ultimate goal of this project, and virtually all studies conducted in the Penn lab. 
Based upon our findings, we presented a simplified model (Figure 20) of 
the way that we expect PGE2 to affect VEGF transcription in Müller cells. The 
EP4 receptor is typically coupled to a Gs G-protein, which increases the activity of 
adenylyl cyclase, and levels of intracellular cAMP (71). It has been established 
that increased cAMP activates PKA, leading to phosphorylation of CREB (and 
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other) transcription factors. Phosphorylated CREB attracts CREB-binding protein 
(CBP), and the CREB-CBP protein complex binds to the CREB response 
element (CRE) on the VEGF gene, stimulating transcription. This over-simplified 
model may be the primary mechanism by which the EP4 receptor affects VEGF 
production in other cell types (215). However, prostanoid receptors activate 
widely different intracellular signaling pathways in both tissue- and cell-specific 
manners. In fact, Fujino et al., in two different studies, demonstrated 1) that the 
EP4 receptor leads to transcriptional activation in a PI3K/ERK-dependent manner 
(237); and 2) that the EP4 receptor can couple to a Gi G-protein, inhibiting cAMP 
production in certain cell types (238). Future experiments should be designed to 
assess specifically: 1) which type of G-protein is activated by EP4 stimulation of 
Müller cells (Gs, Gi, or Gq); 2) which downstream signaling intermediates the G-
protein activates or inhibits (PKA, PKC, PI3K); and 3) specifically how their 
activation leads to transcription of the VEGF gene (which transcription factors are 
activated, and the promoter regions of the VEGF gene they bind). These studies 
will provide the vision research community with a deeper understanding of the 
role of prostanoids in at least one angiogenic cell behavior. A complementary set 
of experiments should be conducted in RMEC in order to ascertain the signaling 
intermediates that mediate angiogenic cell behaviors coupled to EP4 (and other 
prostanoid receptor) activation. 
In conclusion, these studies have contributed much of what is currently 
known about the role of COX-2 and the prostanoids in pathological ocular 
angiogenesis. Although our findings are significant, additional experiments may 
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yield discoveries that, in conjunction with the results presented herein, will 
ultimately benefit the vision community in the form of a precisely targeted, highly 
effective pharmacotherapeutic for diseases such as ROP, PDR, and AMD.  
  106 
APPENDICES  
Appendix 1. Western blot demonstrating the lack of COX-2 protein in Müller cells isolated from 
COX-2 null mice. Müller cells were isolated from wild-type and COX-2 null mice. The cells were 
cultured in DMEM with 10% FBS and 1X antibiotic/antimycotic, and exposed to hypoxia for 24 
hours. Levels of COX-2 protein were assessed by western blot analysis. 
 
Appendix 2. Müller cells isolated from DP, EP1, and EP3 null mice fail to demonstrate reduced 
hypoxia-induced VEGF production. Müller cells were isolated from wild-type and receptor 
knockout mice, cultured in DMEM with 10% FBS and 1X antibiotic/antimycotic, and exposed to 
hypoxia for 24 hours. VEGF was quantified by ELISA. 
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Appendix 3. Preliminary study demonstrating the effect of latanoprost, a PGF2 analog, on VEGF 
production by COX-2 null Müller cells. COX-2 null Müller cells were serum-starved overnight, and 
then treated with increasing concentrations of latanoprost in 2% serum DMEM. Treatment lasted 
6 hours. VEGF was quantified by ELISA. * p < 0.0044 
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